,age,wtkg,hemo,homo,drugs,karnof,oprior,zprior,preanti,race,gender,symptom,treat,cid,cd4-diff,cd8-diff,cd4-8-ratio
0,48,89.8128,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,55,-242,0.7455830388692579
1,61,49.4424,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,895,White,Female,asymptomatic,others,failure,56,172,0.413265306122449
2,45,88.452,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,707,White,Male,asymptomatic,others,censoring,-52,-170,0.15802229762481823
3,47,85.2768,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1399,White,Male,asymptomatic,others,censoring,107,-624,0.18050314465408804
4,43,66.6792,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1352,White,Male,asymptomatic,ZDV only,censoring,-151,-88,0.5793103448275863
5,46,88.9056,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1181,White,Male,asymptomatic,others,censoring,104,200,0.27325581395348836
6,31,73.0296,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,930,White,Male,asymptomatic,ZDV only,failure,-19,-9,0.3446327683615819
7,41,66.2256,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1329,White,Male,asymptomatic,ZDV only,censoring,-35,-169,0.45106861642294716
8,40,82.5552,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1074,White,Male,symtomatic,others,failure,-107,-521,0.3282208588957055
9,35,78.0192,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,964,White,Male,asymptomatic,ZDV only,failure,-89,538,1.0
10,34,95.256,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,897,Non-White,Female,asymptomatic,others,failure,-3,-150,0.6116883116883117
11,38,76.4316,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,461,White,Male,asymptomatic,others,censoring,-110,-150,0.5151515151515151
12,25,68.04,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,852,White,Male,asymptomatic,others,censoring,50,-260,0.33962264150943394
13,34,62.8236,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,342,White,Male,asymptomatic,others,censoring,-22,86,0.19378427787934185
14,49,79.38,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,402,White,Male,asymptomatic,others,failure,20,290,0.15
15,40,83.0088,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,974,White,Male,symtomatic,ZDV only,failure,-60,-570,0.08670520231213873
16,27,67.3,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,875,White,Female,asymptomatic,ZDV only,censoring,90,240,0.4666666666666667
17,46,63.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,881,White,Male,asymptomatic,others,censoring,-10,-190,0.4024390243902439
18,47,94.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1421,White,Male,asymptomatic,others,failure,20,120,0.2535211267605634
19,34,60.3288,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,854,Non-White,Female,asymptomatic,others,censoring,7,-292,0.15937072503419972
20,40,58.0608,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1053,White,Male,asymptomatic,others,censoring,-20,-210,0.3855421686746988
21,39,67.1328,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1057,White,Female,asymptomatic,others,censoring,120,-20,0.49473684210526314
22,30,64.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,837,White,Male,symtomatic,others,failure,-140,-940,0.15436241610738255
23,44,75.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,729,White,Male,asymptomatic,others,censoring,-20,-80,0.40404040404040403
24,38,62.9,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,635,White,Female,asymptomatic,others,failure,-134,-45,0.46802721088435373
25,39,75.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,918,White,Male,asymptomatic,others,failure,40,431,0.3635578583765112
26,35,81.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,882,White,Male,asymptomatic,others,censoring,61,-510,0.20358744394618833
27,28,70.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,886,White,Male,asymptomatic,ZDV only,censoring,-43,-994,0.17903711133400202
28,33,64.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1306,White,Male,asymptomatic,ZDV only,failure,-199,-135,0.2025
29,40,55.566,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,406,Non-White,Female,asymptomatic,others,failure,-45,-242,0.18154080854309687
30,36,81.6,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,86,White,Male,symtomatic,others,censoring,54,77,0.3722397476340694
31,40,70.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,symtomatic,others,censoring,-59,-9,0.3883587786259542
32,34,69.6,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,281,White,Male,asymptomatic,others,failure,82,-517,0.24176857949200375
33,37,73.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-49,187,0.23440712816997944
34,30,50.8,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,24,-69,0.5091743119266054
35,38,87.0,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,67,White,Male,symtomatic,others,censoring,-31,626,0.23319228960977903
36,45,82.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,3,-133,0.5006765899864682
37,29,62.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,635,White,Male,symtomatic,others,failure,-42,-1144,0.09480122324159021
38,48,72.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,49,-157,0.420479302832244
39,34,72.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,16,White,Male,symtomatic,ZDV only,censoring,-78,127,0.21133036282622533
40,27,87.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,118,137,0.3996212121212121
41,37,69.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,-53,-318,0.4257854821235103
42,35,61.4,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,symtomatic,others,censoring,84,-84,0.5757575757575758
43,49,87.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,853,White,Male,asymptomatic,others,censoring,-170,-525,0.41537053979871913
44,34,75.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1379,White,Male,asymptomatic,ZDV only,censoring,10,26,0.41977800201816345
45,33,77.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,512,White,Male,asymptomatic,others,censoring,1,-351,0.23763179237631793
46,43,102.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,672,White,Male,symtomatic,others,failure,-123,-696,0.1330166270783848
47,30,63.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,29,-144,0.47901591895803186
48,24,67.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-139,-170,0.34705075445816186
49,67,71.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,69,-44,0.3148717948717949
50,31,74.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,776,White,Male,asymptomatic,others,censoring,-11,267,0.26549963530269877
51,43,61.6,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,90,White,Female,symtomatic,others,censoring,90,22,0.68
52,39,77.5,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,35,White,Male,asymptomatic,others,censoring,-33,-126,0.40136986301369865
53,37,79.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,54,-458,0.17665369649805449
54,25,68.2668,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,108,-26,0.5468607825295724
55,50,88.9056,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,246,534,0.39983443708609273
56,32,74.1636,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-54,-122,0.5
57,40,74.48112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,51,9,0.3890577507598784
58,30,78.4728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-34,-257,0.5948012232415902
59,26,92.62512,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,failure,125,4,1.2492581602373887
60,47,87.9984,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,290,-67,0.21794871794871795
61,29,72.8028,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,744,White,Female,asymptomatic,others,censoring,-39,6,0.6570680628272252
62,36,53.298,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,213,Non-White,Female,asymptomatic,others,censoring,59,721,0.37544483985765126
63,29,100.2456,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,197,1092,0.2158351409978308
64,29,85.7304,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,144,379,0.21793103448275863
65,41,81.8748,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,360,98,0.11303407247160627
66,33,70.62552,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,141,289,0.3964401294498382
67,28,66.6792,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,106,235,1.116331096196868
68,27,80.15112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,99,-404,0.25712830957230143
69,54,71.2,no hemophilia,homosexual,IV drugs use,70%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,685,White,Male,asymptomatic,others,failure,10,-470,0.14207650273224043
70,41,81.6,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,784,White,Male,asymptomatic,ZDV only,censoring,0,-100,0.25925925925925924
71,36,85.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1182,White,Male,symtomatic,others,failure,-150,-150,0.5294117647058824
72,33,78.6,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,460,White,Male,asymptomatic,others,censoring,90,-280,0.29411764705882354
73,35,64.0,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,28,White,Male,symtomatic,others,censoring,100,70,0.41414141414141414
74,48,59.0,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,163,Non-White,Male,asymptomatic,ZDV only,censoring,-40,410,0.31386861313868614
75,28,75.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,80,170,0.32
76,39,72.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,61,White,Male,asymptomatic,others,censoring,-30,-10,0.3181818181818182
77,25,71.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,90,20,0.5081967213114754
78,36,99.792,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,477,Non-White,Male,asymptomatic,others,censoring,-60,-700,0.2833333333333333
79,42,70.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,560,Non-White,Male,asymptomatic,others,censoring,80,-260,0.2887700534759358
80,33,104.0,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1739,White,Female,asymptomatic,ZDV only,censoring,-350,-30,1.4807692307692308
81,36,52.0,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,667,Non-White,Female,asymptomatic,others,censoring,-130,-170,0.3706896551724138
82,39,54.5,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1057,White,Female,symtomatic,others,censoring,-40,-130,0.2755905511811024
83,28,58.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,890,White,Male,asymptomatic,others,censoring,120,10,0.4351851851851852
84,20,67.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,0,-90,0.22900763358778625
85,27,80.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1477,Non-White,Male,asymptomatic,ZDV only,censoring,-110,-450,0.24019607843137256
86,39,61.0,no hemophilia,no homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,166,White,Female,asymptomatic,others,censoring,80,160,0.22340425531914893
87,37,90.5,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-40,-180,0.24166666666666667
88,27,60.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,872,White,Male,asymptomatic,others,failure,-50,-170,0.17567567567567569
89,31,72.5,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,54,Non-White,Male,asymptomatic,ZDV only,censoring,-20,20,1.05
90,27,79.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-50,-320,0.3137254901960784
91,37,69.0,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,619,White,Male,asymptomatic,others,censoring,90,130,0.5070422535211268
92,40,78.5,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,688,Non-White,Male,asymptomatic,others,censoring,0,-220,0.24778761061946902
93,20,82.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-10,-40,0.5084745762711864
94,31,73.0,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,189,Non-White,Female,symtomatic,others,censoring,-20,-20,0.21621621621621623
95,36,63.5,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-40,-510,0.15976331360946747
96,37,67.5,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,symtomatic,ZDV only,censoring,40,-90,0.46153846153846156
97,22,69.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,failure,20,-220,0.4953271028037383
98,34,86.6376,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,6,35,0.27768595041322314
99,33,83.4624,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,306,White,Male,asymptomatic,others,failure,-15,-84,0.32304038004750596
100,64,77.112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,174,White,Male,asymptomatic,others,censoring,86,367,0.26783216783216784
101,41,79.8336,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,348,White,Male,asymptomatic,others,censoring,-44,-29,0.37652270210409744
102,28,63.2772,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,83,-412,0.19427527405602923
103,47,79.38,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,585,White,Male,asymptomatic,others,censoring,-61,-28,0.24584717607973422
104,70,73.9368,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,674,White,Male,asymptomatic,ZDV only,censoring,-76,-87,0.38269402319357715
105,27,72.576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,110,179,0.29958246346555323
106,42,86.184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,failure,99,294,0.21408045977011494
107,37,65.772,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,35,70,0.4412580943570768
108,30,74.844,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,624,White,Male,asymptomatic,ZDV only,censoring,118,7,0.7564322469982847
109,40,91.6272,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,231,243,0.5246913580246914
110,35,78.9264,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,475,White,Male,asymptomatic,others,censoring,-65,-111,0.5333333333333333
111,36,78.0192,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,104,-89,0.30552291421856637
112,37,86.184,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-5,-254,0.3964539007092199
113,37,83.0088,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-11,-74,0.6064400715563506
114,27,75.7512,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,68,Non-White,Female,asymptomatic,others,censoring,46,5,0.6310679611650486
115,45,66.2256,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,163,62,0.6745283018867925
116,32,84.8232,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,130,White,Male,asymptomatic,others,censoring,51,-144,0.6942590120160214
117,29,82.5552,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,621,White,Male,asymptomatic,ZDV only,censoring,-60,51,0.46984924623115576
118,40,55.3392,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,486,Non-White,Female,asymptomatic,ZDV only,censoring,-26,-473,0.203125
119,47,72.1224,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-68,-154,0.3398835516739447
120,31,44.226,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,symtomatic,others,censoring,-114,-168,0.6167146974063401
121,50,78.9264,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-85,-1180,0.10791057609630267
122,34,83.916,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,305,233,0.3330380868024801
123,41,92.988,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,39,35,0.6747720364741642
124,24,58.5144,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,93,-135,0.6514285714285715
125,39,84.3696,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,160,-111,0.3283261802575107
126,41,111.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,384,White,Male,asymptomatic,others,censoring,-76,-618,0.3075916230366492
127,28,84.3696,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,7,White,Male,asymptomatic,others,censoring,-70,-430,0.3185840707964602
128,29,86.184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,60,260,0.3855421686746988
129,42,57.6072,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,39,White,Male,asymptomatic,others,failure,-40,-220,0.2283464566929134
130,30,88.452,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,265,White,Male,asymptomatic,others,censoring,-70,-480,0.24666666666666667
131,27,66.2256,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-10,80,0.42424242424242425
132,33,62.8236,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1700,White,Male,asymptomatic,others,censoring,860,630,0.2962962962962963
133,44,69.4008,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,105,White,Male,asymptomatic,others,censoring,-40,-80,0.35294117647058826
134,48,78.4728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,975,White,Male,asymptomatic,others,censoring,60,-40,0.2948717948717949
135,37,64.4112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,394,White,Male,asymptomatic,others,censoring,-30,-310,0.36904761904761907
136,43,82.5552,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,330,White,Male,asymptomatic,others,censoring,-30,-350,0.14838709677419354
137,50,77.5656,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,130,-20,0.36538461538461536
138,28,68.4936,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,70,50,0.6363636363636364
139,26,80.514,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,495,White,Male,asymptomatic,others,failure,50,90,0.43859649122807015
140,27,76.2048,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,190,250,0.9565217391304348
141,49,88.452,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,203,White,Male,symtomatic,others,censoring,60,210,0.4230769230769231
142,28,71.1,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,387,White,Female,asymptomatic,others,censoring,270,240,0.6666666666666666
143,30,77.112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,20,-270,0.3764705882352941
144,25,63.504,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,44,White,Female,asymptomatic,others,censoring,-160,-620,0.4304635761589404
145,37,87.5448,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,150,-80,0.2920353982300885
146,42,109.5,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,120,490,0.2807017543859649
147,39,75.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,159,White,Male,asymptomatic,others,censoring,-148,-240,0.6661514683153014
148,30,61.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,53,Non-White,Male,asymptomatic,others,censoring,198,503,0.1506849315068493
149,25,74.844,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,95,-146,0.2951582867783985
150,41,63.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,16,-570,0.15771812080536912
151,24,71.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,-11,-764,0.21217979700338327
152,29,79.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-68,-575,0.26542491268917345
153,31,79.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,217,157,0.588098016336056
154,27,66.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-19,8,0.5121107266435986
155,30,69.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,444,White,Male,asymptomatic,others,failure,54,221,0.23851203501094093
156,35,71.85024,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,66,White,Male,asymptomatic,others,censoring,132,61,0.4466357308584687
157,37,77.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,953,White,Male,asymptomatic,others,censoring,47,-144,0.425832492431887
158,27,91.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,153,White,Male,asymptomatic,others,censoring,59,130,0.2644341801385681
159,36,64.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,174,125,0.423
160,40,78.0,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,511,White,Male,symtomatic,others,censoring,113,217,0.43846153846153846
161,23,55.566,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,431,White,Male,asymptomatic,ZDV only,failure,284,104,0.3897058823529412
162,41,89.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1500,White,Male,asymptomatic,ZDV only,failure,42,835,0.28319783197831977
163,28,59.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,977,White,Male,asymptomatic,ZDV only,censoring,163,181,0.48220064724919093
164,28,75.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1034,White,Male,asymptomatic,others,censoring,-179,-730,0.4261141516810008
165,34,103.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,537,Non-White,Male,asymptomatic,others,censoring,69,-215,0.3415841584158416
166,32,90.5,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,106,311,0.266025641025641
167,42,76.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,666,114,0.755
168,43,72.7,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,807,White,Male,asymptomatic,ZDV only,failure,1,67,0.1943620178041543
169,22,75.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,283,Non-White,Male,asymptomatic,others,censoring,-196,-69,0.40803108808290156
170,65,77.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,89,-13,0.23908216136195412
171,29,70.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,977,White,Male,symtomatic,others,failure,-214,-1258,0.28595132743362833
172,31,85.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,65,Non-White,Male,asymptomatic,others,censoring,378,431,0.4699140401146132
173,42,82.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,827,White,Male,asymptomatic,others,censoring,-53,-154,0.4103671706263499
174,34,105.6888,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,179,82,0.7400346620450606
175,45,72.7,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,76,Non-White,Male,symtomatic,others,censoring,-4,59,0.23457943925233646
176,35,80.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-41,-152,0.7212837837837838
177,30,75.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,ZDV only,censoring,-72,-60,0.27916251246261214
178,34,65.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-343,-309,0.3926332288401254
179,50,72.576,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,148,103,0.3406698564593301
180,38,70.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,38,282,0.23540258143822987
181,29,97.9,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,475,Non-White,Male,asymptomatic,others,censoring,-110,-199,0.4287190082644628
182,35,65.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1725,White,Male,asymptomatic,others,censoring,182,-241,0.23857868020304568
183,54,80.7408,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,588,White,Male,asymptomatic,others,censoring,-30,45,0.8975609756097561
184,32,74.3904,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1160,White,Male,asymptomatic,others,censoring,-22,24,1.445910290237467
185,45,69.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1423,White,Male,asymptomatic,ZDV only,failure,10,-174,0.16065416065416066
186,37,63.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,980,White,Male,asymptomatic,others,censoring,29,214,0.22620380739081747
187,37,64.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,443,Non-White,Male,asymptomatic,others,failure,-3,-111,0.20025429116338206
188,35,65.3184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,14,89,0.4722222222222222
189,39,71.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,137,166,0.6393210749646393
190,37,85.7304,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-232,-377,0.2501506931886679
191,30,78.9264,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-26,578,0.4441366574330563
192,35,74.3904,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,175,Non-White,Male,asymptomatic,ZDV only,censoring,-110,-580,0.26066627703097606
193,30,85.2768,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,325,Non-White,Male,asymptomatic,others,censoring,23,-174,0.2907801418439716
194,37,69.8544,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,383,Non-White,Male,symtomatic,ZDV only,failure,-92,-362,0.18811881188118812
195,34,67.1328,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,448,Non-White,Male,asymptomatic,others,censoring,36,-330,0.19696969696969696
196,36,75.7512,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,602,Non-White,Male,asymptomatic,others,failure,-32,-320,0.22071516646115907
197,50,117.936,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,22,White,Male,asymptomatic,others,censoring,45,12,0.47305389221556887
198,31,76.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,348,White,Male,asymptomatic,others,failure,178,288,0.2985386221294363
199,44,71.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,110,White,Male,asymptomatic,others,censoring,144,10,0.37041420118343193
200,38,69.5,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,113,Non-White,Male,asymptomatic,ZDV only,failure,-196,-375,0.3803245436105477
201,51,87.2,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,113,Non-White,Male,asymptomatic,others,censoring,-11,1,0.2879177377892031
202,27,74.844,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,74,190,0.4793741109530583
203,33,79.1532,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,25,-63,0.46439873417721517
204,39,71.442,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-38,-114,0.13157894736842105
205,25,75.2976,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,113,55,0.8286290322580645
206,40,89.8128,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,271,710,0.42287917737789205
207,40,78.9264,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,132,29,0.6255144032921811
208,30,87.5448,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,124,42,0.44302176696542894
209,30,67.3596,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,225,135,0.4913112164296998
210,38,78.0192,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-203,-574,0.5756035578144854
211,43,73.9368,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,830,Non-White,Female,asymptomatic,others,failure,-111,-537,0.28973660308810173
212,29,70.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,196,47,0.4252199413489736
213,33,70.7616,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,40,121,0.23854289071680376
214,28,115.2144,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,91,Non-White,Female,symtomatic,ZDV only,censoring,1,44,0.26907073509015256
215,33,71.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1645,White,Male,asymptomatic,others,censoring,65,174,0.358087487283825
216,45,67.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1480,Non-White,Male,asymptomatic,others,censoring,359,191,0.0
217,60,51.6,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1472,Non-White,Female,asymptomatic,others,censoring,523,640,0.0
218,29,83.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,132,-123,0.37952559300873906
219,34,70.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,488,White,Male,asymptomatic,others,censoring,71,156,0.688622754491018
220,31,70.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-31,-222,0.18893280632411066
221,32,70.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1598,White,Male,asymptomatic,ZDV only,censoring,-69,-37,0.6637168141592921
222,33,72.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,107,-84,0.40397350993377484
223,46,77.112,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,760,Non-White,Female,asymptomatic,others,censoring,77,24,0.9101123595505618
224,40,81.648,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1051,White,Male,asymptomatic,others,censoring,73,-34,0.5
225,38,79.0,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,507,White,Male,asymptomatic,ZDV only,censoring,-39,45,0.4438860971524288
226,43,73.0296,no hemophilia,homosexual,no IV drugs use,80%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,432,Non-White,Male,symtomatic,others,censoring,18,-58,0.24951830443159922
227,35,96.1632,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1096,White,Male,asymptomatic,others,censoring,95,-299,0.3561859732072498
228,42,74.3904,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,537,White,Male,asymptomatic,others,censoring,-199,216,0.7274611398963731
229,59,72.576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,525,White,Male,asymptomatic,others,failure,-103,-41,0.6101694915254238
230,39,86.184,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,542,Non-White,Male,symtomatic,others,censoring,134,-54,0.2903846153846154
231,36,75.2976,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,910,Non-White,Male,symtomatic,others,censoring,51,-157,0.4716981132075472
232,32,69.4008,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,567,Non-White,Male,symtomatic,ZDV only,censoring,31,354,0.43995098039215685
233,39,80.2872,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,626,White,Male,symtomatic,ZDV only,failure,-35,-190,0.32108843537414966
234,37,78.0192,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,820,White,Male,symtomatic,others,failure,-21,-47,0.20373831775700935
235,55,78.0192,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,852,White,Male,asymptomatic,others,censoring,-178,263,0.33975155279503105
236,37,57.6072,no hemophilia,no homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,698,Non-White,Female,asymptomatic,others,censoring,32,116,0.2553191489361702
237,48,72.1224,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-11,-172,0.36835748792270534
238,30,59.4216,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,617,Non-White,Female,asymptomatic,others,censoring,187,710,0.5406976744186046
239,59,87.9984,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,283,White,Male,asymptomatic,others,censoring,-192,-223,0.6
240,27,85.7304,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,21,Non-White,Male,asymptomatic,others,censoring,-74,-22,0.28365384615384615
241,41,73.4832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,578,White,Male,asymptomatic,ZDV only,censoring,8,257,0.15495732107682206
242,38,79.38,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,768,White,Male,asymptomatic,ZDV only,censoring,31,204,0.6029411764705882
243,40,75.7512,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,179,236,0.3548387096774194
244,40,79.8336,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,615,Non-White,Female,asymptomatic,others,censoring,68,118,0.9755351681957186
245,50,78.4728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,935,White,Male,asymptomatic,ZDV only,failure,-3,40,0.27225130890052357
246,45,74.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1492,White,Male,asymptomatic,others,failure,-32,41,0.21851851851851853
247,47,64.4112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,881,White,Male,asymptomatic,others,censoring,99,180,0.1497851442602824
248,49,100.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1500,White,Male,asymptomatic,ZDV only,censoring,-79,-51,0.856
249,46,66.6792,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1589,White,Male,symtomatic,others,censoring,-14,-581,0.21627118644067797
250,28,68.9472,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,851,White,Male,asymptomatic,others,censoring,47,-198,0.3793103448275862
251,36,72.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1418,White,Male,asymptomatic,others,censoring,-22,-19,0.49290060851926976
252,31,83.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,33,133,0.5978358881875564
253,63,73.4832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-90,-78,0.3648351648351648
254,43,74.3904,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,631,White,Male,asymptomatic,others,censoring,-52,-46,0.6209016393442623
255,37,67.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1279,White,Male,asymptomatic,others,failure,92,-11,0.34763948497854075
256,63,74.3904,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,923,White,Male,asymptomatic,others,censoring,-115,-496,0.28216062544420756
257,38,65.3184,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,250,Non-White,Female,asymptomatic,ZDV only,censoring,-23,-112,0.34452296819787986
258,38,67.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,822,White,Male,asymptomatic,ZDV only,censoring,21,-99,0.3112701252236136
259,39,83.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,563,White,Male,asymptomatic,others,failure,-54,-349,0.2651975683890577
260,34,80.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,325,White,Male,asymptomatic,others,failure,281,467,0.24098867147270855
261,59,87.5448,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,969,White,Male,asymptomatic,others,censoring,-188,-578,0.2519449431478157
262,36,68.04,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-20,-87,0.43290891283055827
263,44,70.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-55,-232,0.24263261296660119
264,33,67.1328,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,608,Non-White,Male,asymptomatic,ZDV only,censoring,-62,-333,0.27200791295746785
265,28,84.3696,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,15,White,Male,symtomatic,others,censoring,210,-208,0.3313356164383562
266,55,90.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,651,White,Male,asymptomatic,others,censoring,-6,-91,0.6256684491978609
267,43,72.576,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,256,517,0.4724104549854792
268,44,85.2768,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,733,White,Male,asymptomatic,ZDV only,censoring,115,560,0.5659863945578232
269,59,84.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,452,Non-White,Male,asymptomatic,ZDV only,failure,-13,186,0.5821596244131455
270,28,72.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,77,45,0.37062256809338523
271,68,90.5,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,618,White,Male,asymptomatic,others,censoring,170,17,0.5272988505747126
272,29,74.6172,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,293,White,Male,asymptomatic,ZDV only,censoring,17,-293,0.23421262989608313
273,33,66.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1240,Non-White,Male,asymptomatic,others,censoring,9,-108,0.2629151291512915
274,33,66.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,123,-24,0.28019323671497587
275,34,66.6792,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,196,376,0.25777202072538863
276,29,49.80528,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,144,White,Female,asymptomatic,ZDV only,censoring,6,137,0.576271186440678
277,28,78.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,433,White,Male,asymptomatic,others,failure,-6,-222,0.2152046783625731
278,38,86.2,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,286,White,Male,asymptomatic,others,failure,-52,-14,0.5208333333333334
279,28,85.5036,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,778,White,Male,asymptomatic,others,censoring,82,538,0.2329988851727982
280,21,59.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,291,Non-White,Male,asymptomatic,others,censoring,64,208,0.46866840731070497
281,22,71.6688,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,948,White,Male,asymptomatic,others,censoring,18,-52,0.33682830930537355
282,59,59.8752,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,872,White,Male,asymptomatic,others,failure,-79,-9,0.29271916790490343
283,35,73.0296,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-8,-187,0.27386363636363636
284,36,75.5,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,70,White,Male,asymptomatic,ZDV only,censoring,67,138,0.1774406332453826
285,48,91.1736,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1087,White,Male,asymptomatic,others,censoring,457,810,0.11898016997167139
286,46,87.318,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,940,White,Male,symtomatic,ZDV only,censoring,-32,92,0.47984267453294
287,31,73.0296,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,181,White,Male,symtomatic,ZDV only,censoring,244,748,0.20565749235474007
288,25,65.3184,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,290,Non-White,Female,asymptomatic,others,censoring,18,-14,0.4298469387755102
289,38,88.5,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,94,White,Male,asymptomatic,ZDV only,failure,31,-41,0.40790842872008326
290,54,71.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,380,White,Male,asymptomatic,others,censoring,22,-26,0.18730553827006846
291,43,85.7304,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,630,White,Male,symtomatic,others,censoring,-47,-431,0.2571090047393365
292,54,68.4936,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,2489,Non-White,Male,asymptomatic,ZDV only,failure,19,172,0.2574102964118565
293,40,92.0808,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,669,White,Male,symtomatic,others,failure,-27,69,0.311731843575419
294,46,80.7408,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,936,White,Male,asymptomatic,others,failure,-22,99,0.4602888086642599
295,34,87.5448,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,25,-45,0.5016447368421053
296,32,84.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,11,39,0.5813253012048193
297,31,79.8336,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,29,32,0.5535006605019815
298,33,71.8956,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,34,262,0.4260614934114202
299,35,77.0,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,103,242,0.8668639053254438
300,33,55.0,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,236,Non-White,Female,asymptomatic,others,censoring,-51,-125,0.6021080368906456
301,33,68.6,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,906,White,Female,asymptomatic,others,censoring,-69,-41,0.18181818181818182
302,32,81.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-108,-449,0.38009049773755654
303,39,81.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,73,-20,0.346448087431694
304,46,123.3792,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,37,100,0.5612998522895125
305,50,65.772,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-112,-264,0.36891117478510027
306,26,74.844,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,9,-32,0.4774193548387097
307,45,72.1224,no hemophilia,homosexual,IV drugs use,70%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,ZDV only,censoring,57,-17,0.15061898211829436
308,28,75.7512,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-27,-136,0.2679814385150812
309,23,87.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,-82,-358,0.2677083333333333
310,42,50.3496,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-144,-92,0.7060301507537688
311,42,57.8,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,161,White,Female,asymptomatic,others,censoring,6,229,0.6328502415458938
312,31,71.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,46,292,0.2773109243697479
313,42,91.1736,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,111,98,0.21128154379020286
314,40,90.72,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-141,-578,0.29904632152588556
315,31,71.6688,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-27,-130,0.7094395280235988
316,41,84.3696,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-56,-310,0.23900293255131966
317,33,78.3,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,symtomatic,others,censoring,19,-156,0.674937965260546
318,27,81.648,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-4,-189,0.5778145695364238
319,29,111.5856,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,3,-72,0.6772616136919315
320,39,80.0604,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,38,-148,0.3471164309031556
321,21,96.6168,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-27,-67,0.6548507462686567
322,35,87.9984,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,43,-395,0.1544811320754717
323,30,62.5968,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,ZDV only,censoring,-56,-44,0.3367521367521368
324,38,111.3588,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,0,886,0.3248730964467005
325,57,63.2772,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,122,White,Female,asymptomatic,others,censoring,112,12,0.3
326,33,92.5344,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,93,74,0.6598930481283423
327,38,85.7304,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,122,149,0.4275210084033613
328,44,82.5552,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-57,-41,0.3894297635605007
329,30,88.9056,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-221,-276,0.8313253012048193
330,41,73.4832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-33,-260,0.5392976588628763
331,66,84.3696,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-63,-296,0.3267663043478261
332,53,91.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,15,-99,0.432
333,31,87.9984,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-17,-390,0.4614065180102916
334,40,74.52648,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,133,White,Female,asymptomatic,others,failure,-133,55,0.8195020746887967
335,37,72.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,969,White,Male,symtomatic,others,censoring,164,-607,0.2221269296740995
336,44,78.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,902,White,Male,symtomatic,others,failure,-233,72,0.22525970475669765
337,56,83.1,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,951,White,Male,asymptomatic,others,censoring,-30,-200,0.5654853620955316
338,39,80.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1582,White,Male,asymptomatic,others,censoring,-45,-288,0.3160493827160494
339,38,78.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,940,White,Male,asymptomatic,others,censoring,-9,-281,0.3706806282722513
340,29,66.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1509,White,Male,asymptomatic,ZDV only,censoring,-91,-208,0.6051612903225806
341,52,67.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,773,White,Male,asymptomatic,others,failure,-96,-230,0.2725450901803607
342,37,76.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1487,White,Male,asymptomatic,ZDV only,censoring,-182,-664,0.5262039660056658
343,34,78.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,931,White,Male,asymptomatic,others,censoring,287,206,0.40705128205128205
344,39,75.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,616,White,Male,symtomatic,others,failure,116,386,0.17367853290183388
345,47,73.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1081,White,Male,asymptomatic,ZDV only,censoring,-30,23,0.3117583603020496
346,40,76.2048,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1066,White,Male,asymptomatic,others,censoring,150,493,0.31776556776556775
347,48,72.576,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,175,White,Male,asymptomatic,ZDV only,censoring,-199,-148,0.7961038961038961
348,54,76.2048,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,945,White,Male,asymptomatic,others,failure,-35,-211,0.35701906412478335
349,57,92.0808,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,329,White,Male,asymptomatic,others,failure,1,1,0.36666666666666664
350,43,57.1536,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,27,245,0.6004901960784313
351,32,86.184,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,396,Non-White,Male,asymptomatic,ZDV only,failure,5,-60,0.3793103448275862
352,48,83.0088,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,68,-250,0.32217573221757323
353,32,98.658,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,473,Non-White,Male,asymptomatic,others,failure,7,-153,0.10128847530422333
354,42,70.7616,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,503,White,Male,symtomatic,ZDV only,failure,-68,-249,0.5195936139332366
355,32,68.9472,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,908,White,Male,symtomatic,others,censoring,-4,-23,0.33288590604026846
356,30,84.8232,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-53,6,1.1615720524017468
357,33,57.1536,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,87,-58,0.34461152882205515
358,34,79.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,134,229,0.09501845018450185
359,38,95.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-40,-188,0.6596774193548387
360,34,73.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,76,-618,0.08880516684607104
361,31,95.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,31,-108,0.6327345309381237
362,26,77.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-65,-414,0.2983050847457627
363,29,89.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1114,Non-White,Male,symtomatic,others,failure,52,978,0.24160206718346253
364,33,97.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,358,White,Male,asymptomatic,ZDV only,failure,-223,-713,0.2885408079142622
365,29,83.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-63,-425,0.43162393162393164
366,28,76.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,52,185,0.29402756508422667
367,25,73.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-136,-511,0.4743975903614458
368,36,88.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,76,105,0.9119170984455959
369,47,91.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,58,-657,0.15141351221849544
370,28,67.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,140,5,0.12181303116147309
371,28,65.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-143,-557,0.2713780918727915
372,48,68.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-47,-725,0.3016129032258065
373,22,58.2876,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,380,Non-White,Male,asymptomatic,others,censoring,42,84,0.4097087378640777
374,40,78.4728,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,832,Non-White,Male,asymptomatic,ZDV only,censoring,63,162,0.6193853427895981
375,25,50.3496,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,746,White,Male,asymptomatic,others,failure,-51,91,0.9802816901408451
376,34,70.7616,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,15,-196,0.6194895591647331
377,20,47.4012,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,123,101,0.32123212321232125
378,36,78.0192,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,-57,-113,0.5533428165007113
379,34,68.04,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,ZDV only,failure,3,214,0.13599348534201955
380,28,58.968,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,34,-11,0.6351351351351351
381,37,89.3592,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,126,79,1.0
382,45,81.4212,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,37,White,Male,asymptomatic,ZDV only,failure,-386,-791,0.583916083916084
383,30,73.6,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,94,-143,0.5105328376703842
384,27,71.8,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-5,-120,0.27136150234741785
385,33,86.184,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,39,93,0.34863195057369817
386,43,81.4212,no hemophilia,homosexual,no IV drugs use,80%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,740,White,Male,symtomatic,others,censoring,35,81,0.610738255033557
387,29,76.2048,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-32,-72,0.42332613390928725
388,46,74.6172,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,316,White,Male,asymptomatic,others,censoring,142,-641,0.08115015974440895
389,30,108.864,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,12,White,Male,asymptomatic,others,censoring,-84,-49,0.5955056179775281
390,36,73.71,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,672,White,Male,asymptomatic,others,censoring,-50,-205,0.40350877192982454
391,21,63.9576,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,415,Non-White,Male,symtomatic,others,censoring,-72,619,0.4935779816513762
392,35,63.0504,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,178,-289,0.2570194384449244
393,25,75.2976,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,345,Non-White,Male,asymptomatic,others,failure,33,-600,0.17834394904458598
394,27,70.308,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-72,62,1.1382978723404256
395,28,70.7616,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,-53,168,0.7108433734939759
396,48,63.0504,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,839,White,Male,symtomatic,others,failure,-126,243,0.3215434083601286
397,26,101.8332,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,692,White,Male,asymptomatic,ZDV only,censoring,55,-44,0.49022801302931596
398,29,84.8232,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,78,White,Male,asymptomatic,others,censoring,496,168,0.500459981600736
399,29,73.4832,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,99,Non-White,Female,asymptomatic,others,censoring,-17,-99,0.5454545454545454
400,48,79.8336,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,311,White,Male,asymptomatic,others,failure,-31,-49,0.26716738197424894
401,35,69.4008,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1650,Non-White,Male,asymptomatic,others,failure,75,174,0.5577956989247311
402,39,71.6688,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,953,Non-White,Male,asymptomatic,ZDV only,censoring,167,13,0.646969696969697
403,39,99.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,748,White,Male,asymptomatic,others,failure,-110,-632,0.3225806451612903
404,36,85.7304,hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,537,White,Male,symtomatic,others,failure,115,1,0.10403050108932461
405,28,63.0504,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,778,Non-White,Male,asymptomatic,others,censoring,112,389,0.5007974481658692
406,33,69.8544,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,603,White,Male,asymptomatic,ZDV only,censoring,31,-39,0.272264631043257
407,29,71.71416,hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,563,White,Male,asymptomatic,others,censoring,-38,-17,0.39055299539170507
408,26,74.844,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1529,White,Male,asymptomatic,ZDV only,censoring,-43,-146,0.4404517453798768
409,48,83.916,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,997,White,Male,asymptomatic,others,censoring,225,274,0.4
410,32,60.7824,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,20,White,Male,asymptomatic,others,censoring,-10,-944,0.2252851711026616
411,41,80.7408,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1076,White,Male,asymptomatic,others,censoring,25,-261,0.2669603524229075
412,33,73.4832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1357,White,Male,asymptomatic,others,censoring,-95,-307,0.4556149732620321
413,27,75.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,676,White,Male,asymptomatic,others,censoring,98,-80,0.40625
414,28,68.9472,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1444,White,Male,asymptomatic,ZDV only,failure,37,-33,0.23634735899731424
415,63,56.4732,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,170,White,Male,asymptomatic,others,failure,6,-61,0.11482889733840304
416,47,68.9472,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,853,Non-White,Male,symtomatic,others,failure,-3,-416,0.18166526492851134
417,36,83.916,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,7,White,Male,asymptomatic,ZDV only,failure,63,379,0.31092436974789917
418,37,57.1536,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,811,Non-White,Male,symtomatic,others,censoring,196,191,0.2766439909297052
419,42,68.4936,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,840,White,Male,symtomatic,others,censoring,97,147,0.4670406732117812
420,35,69.4008,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,41,White,Male,symtomatic,others,censoring,147,174,0.23053435114503817
421,33,78.0192,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,957,White,Male,asymptomatic,others,failure,-17,-435,0.19984802431610943
422,34,77.5656,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,372,White,Male,symtomatic,others,censoring,42,-94,0.34823529411764703
423,39,59.8752,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,671,White,Male,symtomatic,others,censoring,83,228,0.24662162162162163
424,38,77.112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,872,White,Male,symtomatic,others,censoring,56,33,0.3148148148148148
425,33,55.7928,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,964,White,Male,asymptomatic,others,censoring,-285,-2370,0.2460902921215698
426,32,76.2048,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1143,White,Male,asymptomatic,others,censoring,81,161,0.4203125
427,31,86.6376,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,717,Non-White,Male,asymptomatic,others,censoring,-2,-256,0.34990253411306044
428,36,85.2768,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1163,White,Male,asymptomatic,others,censoring,-131,-706,0.29411764705882354
429,27,61.236,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,939,White,Male,symtomatic,others,censoring,121,382,0.3028118240807498
430,15,59.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,896,White,Male,asymptomatic,others,censoring,-30,-88,0.5641025641025641
431,17,92.7,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,768,White,Male,asymptomatic,others,censoring,85,-46,0.2925407925407925
432,38,68.9472,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,993,White,Male,symtomatic,ZDV only,censoring,72,-16,0.3330781010719755
433,43,72.576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,902,White,Male,symtomatic,others,censoring,105,-76,0.5
434,39,85.9572,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1038,White,Male,asymptomatic,others,censoring,107,140,0.3807740324594257
435,38,82.5552,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,768,Non-White,Male,symtomatic,others,failure,11,-455,0.15792610250297973
436,31,76.6584,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1313,White,Male,symtomatic,others,failure,123,-72,0.12528301886792453
437,35,83.0088,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,134,White,Male,symtomatic,others,censoring,-152,-441,0.25015832805573146
438,38,86.8644,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-64,-305,0.4592422502870264
439,41,87.9984,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-18,-288,0.2665056360708535
440,32,82.5552,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,175,290,0.48148148148148145
441,46,92.0808,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,191,512,0.1964133219470538
442,32,78.4728,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1175,Non-White,Male,asymptomatic,others,failure,-154,-654,0.28855325914149443
443,29,73.9368,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,178,246,0.19444444444444445
444,29,79.8336,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-17,-204,0.36543654365436545
445,34,71.442,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,106,134,0.39303482587064675
446,33,70.7616,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,63,-144,0.3392857142857143
447,20,72.576,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,743,Non-White,Male,asymptomatic,others,censoring,-60,-18,0.6733576642335767
448,49,70.0812,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,151,-150,0.2906666666666667
449,31,85.2768,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,95,White,Male,symtomatic,others,censoring,133,-114,0.19064327485380117
450,30,84.5964,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,129,White,Male,asymptomatic,ZDV only,failure,-93,-666,0.13175675675675674
451,33,69.8544,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,277,Non-White,Male,asymptomatic,ZDV only,censoring,122,236,0.32045654082528535
452,32,60.5556,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,31,White,Female,asymptomatic,ZDV only,censoring,-81,-178,0.6026936026936027
453,32,82.5552,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-94,-161,0.838150289017341
454,33,74.3904,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,919,Non-White,Male,symtomatic,others,censoring,-120,-486,0.13734567901234568
455,35,65.772,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,43,150,0.8569105691056911
456,22,64.638,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,140,67,0.27510460251046026
457,26,78.0192,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,807,White,Male,symtomatic,others,failure,256,828,0.48046875
458,37,77.3388,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,232,White,Male,symtomatic,others,failure,-157,-147,0.6624405705229794
459,29,78.4728,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,267,White,Male,asymptomatic,others,censoring,224,581,0.31865042174320524
460,34,62.5968,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,260,14,0.4821173104434907
461,30,70.7616,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1826,White,Male,symtomatic,others,censoring,44,-536,0.22066822066822067
462,30,78.0192,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-170,-263,0.4723618090452261
463,32,92.0808,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,42,93,0.7950819672131147
464,31,73.2564,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,260,White,Male,asymptomatic,others,censoring,-20,-560,0.23550087873462214
465,39,75.2976,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,847,White,Male,symtomatic,others,censoring,9,82,0.565365025466893
466,35,93.4416,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1200,Non-White,Male,asymptomatic,ZDV only,failure,-28,-365,0.168997668997669
467,28,67.5864,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,51,White,Male,asymptomatic,others,censoring,-11,39,0.3613933236574746
468,30,64.8648,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,188,-94,0.3016194331983806
469,43,89.3592,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1118,White,Male,asymptomatic,ZDV only,censoring,107,841,0.32222222222222224
470,30,82.5552,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,389,White,Male,symtomatic,others,censoring,122,101,0.10700934579439253
471,37,83.4624,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1240,Non-White,Male,asymptomatic,others,censoring,-6,-39,0.44755244755244755
472,52,72.576,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,376,Non-White,Female,asymptomatic,ZDV only,failure,-211,-768,0.26936619718309857
473,37,83.4624,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,217,43,0.34839650145772594
474,60,72.576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,60,72,0.6802721088435374
475,30,51.4836,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,36,176,0.49105914718019256
476,36,73.0296,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,320,-1,0.23574468085106384
477,31,86.4108,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-3,-160,0.4551148225469729
478,27,74.3904,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,ZDV only,censoring,38,-164,0.4839424141749723
479,33,67.1328,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,246,684,0.5457875457875457
480,38,68.04,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,256,105,0.14251207729468598
481,37,79.8336,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,-32,-778,0.12343966712898752
482,39,79.38,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,18,203,0.47088186356073214
483,26,67.8132,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-2,-115,0.2874806800618238
484,45,73.0296,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-69,-280,0.3278894472361809
485,49,90.0396,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,failure,34,-184,0.5
486,30,73.9368,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,28,80,0.459866220735786
487,42,63.0504,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,-34,-85,0.6491228070175439
488,34,82.782,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-9,-459,0.25
489,38,68.04,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,96,483,0.15184049079754602
490,42,85.2768,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,12,391,0.5
491,31,95.256,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,-51,207,0.2601957585644372
492,39,69.8544,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,142,307,0.31061806656101426
493,38,83.4624,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,763,White,Male,asymptomatic,ZDV only,censoring,-153,81,0.3241830065359477
494,37,68.2,no hemophilia,no homosexual,no IV drugs use,80%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,727,White,Male,symtomatic,ZDV only,censoring,97,305,0.723404255319149
495,33,78.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1774,White,Male,asymptomatic,others,censoring,-59,-15,0.45098039215686275
496,33,69.8544,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,191,44,0.5961538461538461
497,36,75.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,446,White,Male,asymptomatic,ZDV only,failure,-26,172,0.3709677419354839
498,43,78.6,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1289,White,Male,asymptomatic,others,censoring,-82,-302,0.3125
499,37,66.6,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1137,White,Male,symtomatic,ZDV only,failure,-85,-517,0.18181818181818182
500,32,63.504,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,794,White,Male,asymptomatic,ZDV only,censoring,7,-69,0.4482758620689655
501,36,82.5552,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1379,White,Male,asymptomatic,others,censoring,308,210,1.4074074074074074
502,50,64.4112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,914,Non-White,Male,asymptomatic,others,failure,48,522,0.25
503,37,74.3904,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,739,White,Male,asymptomatic,others,censoring,71,-233,0.44642857142857145
504,41,75.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1260,White,Male,asymptomatic,others,censoring,-136,-790,0.2647058823529412
505,35,74.3904,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,924,Non-White,Male,asymptomatic,others,censoring,-32,-96,0.5454545454545454
506,57,80.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,932,White,Male,asymptomatic,others,censoring,66,150,0.3548387096774194
507,43,76.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,724,White,Male,asymptomatic,ZDV only,censoring,-60,10,0.4883720930232558
508,62,83.4624,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,108,409,0.27692307692307694
509,29,68.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,779,Non-White,Male,asymptomatic,others,failure,91,48,0.27419354838709675
510,38,78.9264,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,2342,White,Female,asymptomatic,others,censoring,456,288,1.4411764705882353
511,49,60.7824,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,777,White,Male,asymptomatic,others,censoring,-16,32,0.38596491228070173
512,27,71.2152,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,28,-204,0.35
513,19,68.04,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,85,Non-White,Male,asymptomatic,others,censoring,-107,129,0.45098039215686275
514,41,80.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,335,White,Male,symtomatic,others,censoring,-170,-174,0.5111111111111111
515,28,65.5,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,206,Non-White,Male,asymptomatic,others,failure,-55,-248,0.42207792207792205
516,26,70.0812,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-239,-142,0.9210526315789473
517,28,68.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,192,278,0.3442622950819672
518,68,70.7616,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1770,White,Male,asymptomatic,others,failure,-6,-382,0.20588235294117646
519,33,73.0296,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,609,White,Male,asymptomatic,others,censoring,58,20,0.3220338983050847
520,35,97.524,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,889,White,Male,asymptomatic,ZDV only,failure,-34,-215,0.27692307692307694
521,31,66.2256,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,495,708,0.16417910447761194
522,39,74.844,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,586,White,Male,asymptomatic,others,censoring,72,-384,0.25
523,43,62.1432,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1626,White,Male,asymptomatic,others,censoring,58,28,0.9545454545454546
524,42,48.0816,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,493,Non-White,Female,asymptomatic,ZDV only,failure,-128,-122,0.6808510638297872
525,38,79.38,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,325,White,Male,asymptomatic,others,failure,-36,-48,0.22388059701492538
526,47,64.4112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,508,White,Male,asymptomatic,ZDV only,censoring,-21,40,0.673469387755102
527,41,73.9368,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1039,White,Male,asymptomatic,others,failure,76,-133,0.171875
528,38,69.8544,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,189,White,Male,asymptomatic,ZDV only,censoring,-18,356,0.26666666666666666
529,32,87.5448,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-3,-402,0.22727272727272727
530,51,96.1632,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,130,10,0.42592592592592593
531,35,56.7,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,-42,-474,0.2835820895522388
532,40,73.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,31,-160,0.3050847457627119
533,42,59.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,123,White,Male,asymptomatic,ZDV only,censoring,-11,524,0.37254901960784315
534,26,81.0,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,103,White,Male,asymptomatic,others,censoring,80,-70,0.4727272727272727
535,35,66.2256,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,437,White,Male,symtomatic,others,censoring,54,-68,0.24193548387096775
536,39,80.5,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,62,769,0.19444444444444445
537,31,60.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,634,White,Male,asymptomatic,others,censoring,195,480,0.6666666666666666
538,42,79.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,677,White,Male,symtomatic,others,censoring,72,-288,0.3333333333333333
539,32,86.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,710,Non-White,Male,asymptomatic,ZDV only,censoring,-182,-378,0.38095238095238093
540,46,81.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-96,-492,0.4791666666666667
541,58,80.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,483,White,Male,asymptomatic,others,censoring,11,104,0.4406779661016949
542,33,61.2,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,383,White,Female,asymptomatic,others,censoring,34,-202,0.359375
543,43,92.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,295,White,Male,asymptomatic,others,censoring,76,57,0.3829787234042553
544,37,107.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,204,White,Male,asymptomatic,others,censoring,-115,-598,0.17142857142857143
545,41,75.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-14,-104,0.38333333333333336
546,23,66.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-36,-132,0.7
547,35,76.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-42,-84,0.38095238095238093
548,34,79.2,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,1,-150,0.3387096774193548
549,32,80.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-15,69,0.42857142857142855
550,30,59.9,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,failure,169,-426,0.14864864864864866
551,35,69.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,31,306,0.3148148148148148
552,40,78.0192,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,870,Non-White,Female,symtomatic,ZDV only,censoring,-149,110,0.7507122507122507
553,45,53.9784,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,479,White,Female,asymptomatic,others,censoring,223,91,0.6530612244897959
554,47,78.0192,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1598,White,Male,asymptomatic,others,censoring,22,-114,0.568407960199005
555,30,67.3596,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1316,White,Male,asymptomatic,others,failure,-192,-626,0.26735921268452706
556,34,57.1536,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,821,Non-White,Female,asymptomatic,others,censoring,96,150,0.42303306727480045
557,42,72.576,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,861,Non-White,Male,asymptomatic,others,censoring,81,-18,0.22469823584029713
558,32,75.5244,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,411,Non-White,Female,asymptomatic,others,failure,28,343,0.3333333333333333
559,36,84.8232,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,463,White,Female,asymptomatic,ZDV only,failure,-69,-127,0.46301369863013697
560,26,47.4012,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,632,Non-White,Female,asymptomatic,ZDV only,censoring,-18,72,0.4706616729088639
561,32,78.9264,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,917,White,Male,asymptomatic,others,censoring,31,-236,0.3425572519083969
562,38,55.3392,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1068,Non-White,Female,asymptomatic,others,censoring,62,387,0.18901890189018902
563,27,59.8752,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,40,250,0.8103727714748784
564,55,82.1016,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,587,White,Male,asymptomatic,others,censoring,-84,22,0.212430426716141
565,35,66.6792,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,22,-296,0.3575418994413408
566,32,70.308,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,84,192,0.8003875968992248
567,35,94.8024,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,100,White,Male,asymptomatic,ZDV only,failure,-74,-149,0.3492063492063492
568,27,71.2152,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,144,173,0.29057337220602525
569,22,55.7928,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,90,-155,0.9748427672955975
570,28,45.36,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,failure,-43,-131,0.34615384615384615
571,31,75.2976,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,343,Non-White,Female,asymptomatic,others,failure,-143,-260,0.4537037037037037
572,24,70.7616,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,75,White,Male,asymptomatic,ZDV only,censoring,-322,-438,0.49160671462829736
573,44,60.3288,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,817,White,Male,asymptomatic,ZDV only,failure,-154,-235,0.6307947019867549
574,33,79.1532,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,311,White,Male,symtomatic,others,failure,46,71,0.18855656697009102
575,26,63.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,35,White,Male,asymptomatic,others,censoring,203,402,0.731610337972167
576,23,84.1428,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,243,White,Male,asymptomatic,others,censoring,308,458,0.5637181409295352
577,29,78.4728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-7,-167,0.5121602288984263
578,32,78.4728,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-135,-633,0.26135615536537193
579,27,77.112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-76,-178,0.2467866323907455
580,36,118.3896,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,26,696,0.10008517887563884
581,35,83.4624,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-116,-153,0.43399810066476735
582,30,87.0912,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,230,White,Male,asymptomatic,others,failure,-119,266,0.7996918335901386
583,64,72.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,217,145,0.1589648798521257
584,36,68.04,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,failure,276,-79,0.31273408239700373
585,30,75.7512,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,failure,-135,-537,0.4194577352472089
586,33,69.8544,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,105,Non-White,Female,asymptomatic,ZDV only,censoring,5,-164,0.46114649681528663
587,25,63.0504,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,157,-384,0.2540983606557377
588,28,73.71,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,94,148,0.5911251980982567
589,32,63.504,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-87,-320,0.4655380894800484
590,22,72.576,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,120,-195,0.3095435684647303
591,33,70.5348,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,44,20,0.8191489361702128
592,43,77.112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,105,-282,0.22696860524961399
593,34,64.638,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-187,157,0.5961538461538461
594,30,89.8128,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,382,369,0.32038834951456313
595,24,61.6896,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,34,Non-White,Female,asymptomatic,others,failure,21,406,0.15825169555388094
596,32,90.72,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,64,-131,0.2857142857142857
597,32,75.978,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,312,Non-White,Female,asymptomatic,ZDV only,censoring,-64,-217,0.41682242990654206
598,45,66.6792,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,327,Non-White,Female,asymptomatic,others,censoring,287,322,0.17588652482269504
599,20,66.6792,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,921,White,Male,asymptomatic,others,censoring,41,-114,0.46445131375579596
600,30,66.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1902,Non-White,Male,asymptomatic,others,censoring,190,590,10.0
601,28,68.81112,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1586,White,Male,asymptomatic,others,censoring,57,5,0.5904255319148937
602,31,75.2976,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1538,White,Male,symtomatic,others,failure,-53,-64,0.21406347230864967
603,26,77.5656,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1540,White,Male,symtomatic,ZDV only,failure,-43,157,0.2952941176470588
604,46,64.95552,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1098,White,Male,symtomatic,others,failure,24,146,0.33636363636363636
605,50,63.7308,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,931,White,Male,symtomatic,others,failure,-29,48,0.40966921119592875
606,37,65.772,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1203,White,Female,asymptomatic,ZDV only,failure,-34,266,0.4107142857142857
607,35,73.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1898,White,Male,asymptomatic,others,failure,-157,-218,0.2939972714870396
608,36,62.5968,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,853,White,Female,asymptomatic,others,censoring,179,225,0.19739478957915832
609,37,47.8,hemophilia,no homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,391,White,Male,asymptomatic,ZDV only,censoring,-40,0,0.40476190476190477
610,37,68.04,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,658,White,Male,asymptomatic,others,censoring,99,-3,0.41414141414141414
611,25,78.10992,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,517,White,Male,symtomatic,ZDV only,censoring,-54,91,0.3888354186717998
612,33,80.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,414,White,Male,asymptomatic,others,censoring,70,-180,0.2
613,38,67.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,420,White,Female,asymptomatic,others,censoring,-40,-180,0.5476190476190477
614,39,104.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,245,White,Male,asymptomatic,others,censoring,-60,-370,0.15384615384615385
615,37,65.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,289,White,Male,symtomatic,others,censoring,230,-30,0.29365079365079366
616,39,62.5968,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1250,White,Male,asymptomatic,others,censoring,50,210,0.205607476635514
617,37,77.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,411,White,Male,asymptomatic,ZDV only,censoring,-40,-280,0.5357142857142857
618,31,90.35712,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,976,White,Male,asymptomatic,ZDV only,censoring,116,577,0.42645074224021595
619,58,68.4936,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1142,White,Female,asymptomatic,others,censoring,134,308,0.3584905660377358
620,32,80.514,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,237,White,Male,asymptomatic,others,censoring,515,842,0.323890462700661
621,32,64.1844,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,388,White,Male,asymptomatic,ZDV only,censoring,-46,-369,0.193943763518385
622,27,65.3184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,151,-213,0.22857142857142856
623,31,65.772,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,190,18,0.3443181818181818
624,36,78.9264,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,19,400,0.18053375196232338
625,39,66.2256,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,154,Non-White,Male,asymptomatic,others,censoring,221,-827,0.2002194185408667
626,38,93.4416,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-54,-339,0.37725752508361204
627,40,74.3904,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,655,White,Male,asymptomatic,others,censoring,137,-78,0.25395569620253167
628,38,64.8648,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,152,-57,0.37735849056603776
629,36,120.6576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,132,White,Male,asymptomatic,others,censoring,-46,-433,0.19153365718251214
630,32,87.5448,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,160,White,Male,asymptomatic,others,failure,-6,-32,0.1968
631,15,50.8032,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1574,White,Male,asymptomatic,others,censoring,-20,-313,0.24173318129988597
632,28,85.2768,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,187,11,0.4695121951219512
633,41,77.112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,142,-12,0.7109634551495017
634,44,51.2568,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,-130,-697,0.16251830161054173
635,37,73.4832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,87,167,0.4115138592750533
636,30,77.112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,25,38,0.7179080824088748
637,25,110.6784,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,-180,-527,0.4284712482468443
638,34,74.6172,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,167,Non-White,Male,symtomatic,others,failure,-199,-127,0.45670225385527874
639,34,74.844,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,420,White,Male,symtomatic,others,censoring,62,-84,0.32689655172413795
640,37,70.9884,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,819,Non-White,Male,asymptomatic,others,censoring,41,15,0.31055276381909547
641,37,56.8,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,920,White,Female,asymptomatic,ZDV only,censoring,90,-62,0.4162962962962963
642,35,48.762,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,failure,35,174,0.4725274725274725
643,39,66.906,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,577,Non-White,Male,asymptomatic,ZDV only,censoring,50,197,0.2329390354868062
644,46,77.112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,735,White,Male,symtomatic,ZDV only,failure,-51,347,0.22408963585434175
645,41,79.8336,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,361,Non-White,Male,symtomatic,others,censoring,-54,-180,0.2981427174975562
646,51,68.4936,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,364,White,Male,symtomatic,others,censoring,-127,-129,0.5718270571827058
647,27,59.6484,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-6,-68,0.6131687242798354
648,39,81.648,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,243,White,Male,asymptomatic,others,failure,-82,63,0.3388842631140716
649,45,82.87272,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,406,Non-White,Male,asymptomatic,others,censoring,25,637,0.22704975473020322
650,30,97.2972,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,302,Non-White,Male,asymptomatic,others,censoring,397,1487,0.36363636363636365
651,41,84.3,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,315,Non-White,Female,asymptomatic,others,censoring,50,50,0.5
652,36,80.0,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,210,-390,0.28708133971291866
653,22,78.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,60,10,0.5901639344262295
654,45,69.0,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,130,-50,0.5645161290322581
655,34,108.864,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,84,234,0.3842239185750636
656,28,90.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1508,Non-White,Male,asymptomatic,others,censoring,-12,-518,0.2336244541484716
657,44,71.2152,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,952,White,Male,asymptomatic,others,censoring,-109,-91,0.5209840810419681
658,29,80.7408,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,893,Non-White,Male,asymptomatic,others,censoring,-111,7,0.6970260223048327
659,37,81.648,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,585,White,Male,asymptomatic,others,censoring,36,-216,0.16369278510473234
660,33,67.5864,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,868,Non-White,Male,asymptomatic,others,failure,-102,189,1.2198142414860682
661,32,69.4008,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,910,White,Male,asymptomatic,others,censoring,105,189,0.34396671289875175
662,33,76.6584,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,875,White,Male,asymptomatic,others,failure,-85,-87,0.41509433962264153
663,25,64.4112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,659,Non-White,Male,asymptomatic,others,failure,80,313,0.5451388888888888
664,58,63.504,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,141,Non-White,Male,asymptomatic,others,censoring,22,123,0.5
665,25,59.8752,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,677,White,Male,asymptomatic,others,censoring,-12,257,0.22135706340378197
666,52,68.04,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,270,Non-White,Male,asymptomatic,ZDV only,censoring,70,144,0.6860215053763441
667,26,58.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,445,White,Male,asymptomatic,ZDV only,failure,-19,243,0.5551470588235294
668,44,104.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,42,White,Male,asymptomatic,others,censoring,-163,-253,0.7735537190082644
669,42,55.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-193,274,0.4896810506566604
670,46,72.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,199,-1047,0.19699326075686885
671,34,96.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,273,White,Male,asymptomatic,others,censoring,-173,-158,1.0967238689547583
672,26,79.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,125,347,0.2
673,32,59.4216,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,96,38,0.3387096774193548
674,41,73.2,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,371,White,Male,asymptomatic,others,censoring,63,252,0.2974559686888454
675,38,75.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,31,Non-White,Male,asymptomatic,others,censoring,4,212,0.5158069883527454
676,32,57.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-109,496,0.45454545454545453
677,30,70.7616,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,104,White,Female,asymptomatic,others,censoring,182,-403,0.4482758620689655
678,33,88.2252,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,0,27,0.4991243432574431
679,26,61.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,140,Non-White,Male,symtomatic,ZDV only,censoring,83,719,0.2356948228882834
680,29,64.4112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,283,142,0.6064073226544623
681,25,111.132,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,231,-290,0.371499176276771
682,51,60.3288,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,43,92,0.2875494071146245
683,28,60.3288,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,140,-145,0.4384180790960452
684,33,90.2664,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,17,-58,0.28065134099616856
685,33,78.9264,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,58,375,0.35135135135135137
686,40,72.3492,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,126,-762,0.11271676300578035
687,28,88.452,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-75,-503,0.3648854961832061
688,46,74.6172,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-107,61,0.615071283095723
689,49,66.2256,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-75,80,0.6384522370012092
690,43,80.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,937,White,Male,asymptomatic,others,censoring,-44,-60,0.46622516556291393
691,34,83.5,no hemophilia,homosexual,IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,811,White,Male,symtomatic,others,failure,-108,-435,0.2204724409448819
692,36,74.1,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1452,White,Male,asymptomatic,others,failure,-20,-338,0.22392886014551333
693,39,71.8,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,971,White,Male,symtomatic,others,censoring,116,110,0.5302013422818792
694,43,81.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1424,White,Male,asymptomatic,others,censoring,-47,-203,0.413022351797862
695,39,69.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1394,White,Male,asymptomatic,others,censoring,156,51,0.5764705882352941
696,20,66.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,830,White,Male,asymptomatic,others,failure,-59,-822,0.2153846153846154
697,27,88.6,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1005,White,Male,symtomatic,others,censoring,31,-4,1.0263157894736843
698,40,75.9,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1318,White,Male,symtomatic,ZDV only,censoring,9,358,0.28603603603603606
699,50,68.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,959,White,Male,asymptomatic,ZDV only,censoring,-27,-283,0.5182072829131653
700,34,56.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1237,White,Male,symtomatic,others,censoring,-13,-63,0.15119760479041916
701,39,81.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,445,White,Male,symtomatic,others,failure,-540,313,1.028052805280528
702,27,55.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,996,White,Male,asymptomatic,others,censoring,140,220,0.42587601078167114
703,32,79.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,199,White,Male,asymptomatic,others,censoring,82,176,0.7509505703422054
704,35,77.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,722,White,Male,symtomatic,others,failure,-15,-683,0.1644157369348209
705,34,68.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1104,White,Male,asymptomatic,others,censoring,113,58,0.2659380692167577
706,49,84.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1008,White,Male,asymptomatic,others,failure,63,-71,0.5555555555555556
707,41,85.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1131,White,Male,asymptomatic,others,censoring,-114,-265,0.3103448275862069
708,36,77.112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,29,Non-White,Male,asymptomatic,others,censoring,188,472,0.4425956738768719
709,43,81.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,156,48,0.49194414607948445
710,45,66.4,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,224,White,Female,asymptomatic,others,censoring,31,130,0.7215189873417721
711,63,92.0808,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,76,White,Male,asymptomatic,ZDV only,failure,41,167,0.16210045662100456
712,43,70.0812,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,3,-40,0.3704206241519674
713,38,78.2,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,105,White,Male,asymptomatic,others,failure,95,-31,0.21153846153846154
714,43,94.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-54,-250,0.16412661195779601
715,34,75.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,112,White,Male,symtomatic,others,failure,161,263,0.4033850493653032
716,29,105.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,387,White,Male,asymptomatic,others,censoring,135,43,0.5341545352743561
717,35,75.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-47,25,0.3901760889712697
718,31,88.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,20,-24,0.5903614457831325
719,45,76.0,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,866,White,Male,symtomatic,others,failure,66,375,0.2662490211433046
720,36,88.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,65,187,0.34386617100371747
721,38,79.6068,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,116,White,Male,asymptomatic,others,failure,-21,128,0.21852387843704776
722,45,59.0,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,49,White,Male,asymptomatic,others,censoring,-56,129,0.376984126984127
723,30,81.1944,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,566,80,0.0
724,34,79.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,335,White,Male,asymptomatic,ZDV only,failure,-42,8,0.44285714285714284
725,38,87.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,832,White,Male,asymptomatic,others,censoring,30,6,0.22193211488250653
726,29,71.2152,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,420,White,Male,symtomatic,ZDV only,failure,-121,-59,0.235467255334805
727,29,69.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,13,104,0.5866013071895425
728,35,86.6376,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,138,White,Male,asymptomatic,others,censoring,80,-101,0.41500399042298486
729,34,91.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,70,White,Male,asymptomatic,others,censoring,-56,-104,0.3793103448275862
730,27,75.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,20,97,0.23055809698078683
731,31,84.3696,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,78,150,0.6165919282511211
732,43,75.9,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,142,White,Male,asymptomatic,others,censoring,91,-150,0.21517412935323382
733,48,64.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,147,203,0.8832997987927566
734,29,70.308,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,135,White,Male,asymptomatic,ZDV only,censoring,63,142,0.4797570850202429
735,46,75.9,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-30,-12,0.31529850746268656
736,30,71.8956,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-14,-86,0.35036496350364965
737,35,82.3,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,496,White,Male,asymptomatic,others,censoring,163,94,0.3755813953488372
738,31,92.3,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,132,-568,0.1767189384800965
739,53,93.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,62,24,0.30008244023083264
740,34,67.7,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,284,White,Male,asymptomatic,others,censoring,188,223,0.3392070484581498
741,49,63.6,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,397,White,Male,symtomatic,others,censoring,35,215,0.5592334494773519
742,27,78.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,failure,44,174,0.25395927601809953
743,50,83.3,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,50,-79,0.4557109557109557
744,36,67.0,no hemophilia,homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,754,Non-White,Male,asymptomatic,others,censoring,5,566,0.18671875
745,33,70.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1119,White,Male,asymptomatic,ZDV only,failure,-100,-143,0.15657439446366783
746,55,60.7824,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,315,502,0.489851150202977
747,25,83.6892,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,224,-180,0.32771535580524347
748,39,94.5,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,114,White,Male,symtomatic,others,failure,162,473,0.2641843971631206
749,46,67.7,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,73,White,Male,symtomatic,others,failure,-65,-43,0.4411764705882353
750,38,59.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-59,-375,0.5110336817653891
751,44,72.5,no hemophilia,homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,135,White,Male,symtomatic,others,failure,-34,-203,0.19990503323836656
752,50,82.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,119,White,Male,asymptomatic,ZDV only,failure,-48,-299,0.23057953144266338
753,39,73.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,836,White,Male,asymptomatic,others,censoring,106,-20,0.20800889877641823
754,44,76.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,974,White,Male,asymptomatic,ZDV only,failure,-110,-267,0.29818496110630943
755,27,80.9,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,842,Non-White,Male,asymptomatic,others,failure,-78,-676,0.2496798975672215
756,34,80.9,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1452,White,Male,asymptomatic,others,censoring,70,-309,0.13885505481120586
757,27,63.6,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,600,White,Male,asymptomatic,others,censoring,151,-20,0.39299610894941633
758,30,64.5,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1665,White,Male,asymptomatic,others,censoring,145,-283,0.27699530516431925
759,50,77.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,271,44,0.4652631578947368
760,20,71.1,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,132,292,0.4109429569266589
761,38,77.7,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,817,Non-White,Female,asymptomatic,ZDV only,censoring,-15,115,0.7134268537074149
762,48,70.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-36,-333,0.4577893820713664
763,65,60.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,45,-509,0.20535714285714285
764,34,70.0,no hemophilia,no homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,symtomatic,others,censoring,84,146,0.1549673954737246
765,44,82.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,175,112,0.2902621722846442
766,43,69.4008,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,-112,3,0.8219424460431655
767,29,77.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,140,301,0.357
768,33,82.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-151,-360,0.5518672199170125
769,33,78.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,44,-176,0.2882635552505148
770,29,70.0,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,4,-240,0.26564102564102565
771,37,90.9,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-22,-406,0.6527068437180796
772,31,83.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,911,Non-White,Male,asymptomatic,others,censoring,127,744,0.2254016064257028
773,37,77.9,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,949,White,Male,symtomatic,ZDV only,failure,-77,-615,0.2031107044830741
774,23,62.0,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1662,White,Male,asymptomatic,ZDV only,censoring,115,313,0.33869670152855996
775,35,74.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,896,White,Male,asymptomatic,others,censoring,13,141,0.611731843575419
776,42,95.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,912,White,Male,asymptomatic,others,failure,20,-77,0.5629139072847682
777,46,86.1,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1423,White,Male,asymptomatic,ZDV only,failure,-223,-1054,0.1665773968934119
778,42,74.6,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1303,White,Male,symtomatic,ZDV only,failure,-77,-552,0.18341463414634146
779,38,90.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,917,White,Male,symtomatic,ZDV only,censoring,18,-245,0.37897310513447435
780,37,74.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,903,White,Male,asymptomatic,others,censoring,51,38,0.3055555555555556
781,30,73.4832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,540,White,Male,asymptomatic,others,censoring,170,79,0.8202614379084967
782,35,66.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1729,White,Male,asymptomatic,others,failure,326,431,0.36033519553072624
783,45,62.0,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,933,White,Male,asymptomatic,ZDV only,failure,-116,-706,0.16680361544782252
784,32,90.2,no hemophilia,homosexual,no IV drugs use,70%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1696,White,Male,asymptomatic,ZDV only,failure,3,32,0.3961661341853035
785,42,78.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,434,White,Male,asymptomatic,ZDV only,censoring,109,458,0.40616966580976865
786,43,88.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,996,Non-White,Male,symtomatic,others,censoring,-23,291,0.6413255360623782
787,59,86.0,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,969,White,Male,asymptomatic,ZDV only,censoring,4,112,0.49122807017543857
788,37,93.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,917,Non-White,Male,asymptomatic,ZDV only,failure,9,303,0.2684563758389262
789,49,99.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,931,White,Male,symtomatic,others,failure,-83,-541,0.15942028985507245
790,40,78.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1306,White,Male,symtomatic,others,censoring,-115,-243,0.3384512683578104
791,48,70.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1474,White,Male,asymptomatic,others,censoring,79,65,0.38474295190713104
792,45,76.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1348,White,Male,asymptomatic,others,censoring,15,-308,0.23648648648648649
793,38,70.0,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1287,White,Male,asymptomatic,ZDV only,censoring,-169,-97,0.6749271137026239
794,45,85.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1314,White,Male,asymptomatic,others,censoring,-48,-250,0.2298474945533769
795,41,73.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,913,White,Male,asymptomatic,others,censoring,12,75,0.3722304283604136
796,31,78.1,hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1174,White,Male,asymptomatic,others,censoring,104,378,1.8759124087591241
797,33,89.9,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,945,White,Male,asymptomatic,others,failure,-231,116,0.5482071713147411
798,28,66.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,909,White,Male,asymptomatic,others,censoring,-62,-455,0.16201497617426822
799,47,68.4,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,56,White,Male,asymptomatic,others,failure,-77,-236,0.5111111111111111
800,38,59.5,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,437,White,Male,symtomatic,others,censoring,-106,-107,0.5292887029288703
801,58,91.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,58,-113,0.5006802721088436
802,38,81.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,7,-152,0.7231467473524962
803,53,98.5,no hemophilia,homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,248,Non-White,Male,asymptomatic,ZDV only,failure,49,166,0.4146341463414634
804,30,64.4,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,43,240,0.39975550122249387
805,27,56.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,33,-231,0.38474295190713104
806,42,76.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,2071,White,Male,asymptomatic,others,failure,-60,-195,0.2502134927412468
807,39,64.5,no hemophilia,homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,101,White,Male,asymptomatic,others,censoring,14,365,0.17972070431086826
808,38,76.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,297,Non-White,Male,asymptomatic,ZDV only,failure,52,207,0.5
809,29,79.9,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,186,-24,0.24976437323279924
810,27,87.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,892,White,Male,symtomatic,others,failure,158,323,0.35105204872646734
811,27,72.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,106,White,Female,asymptomatic,others,censoring,92,55,0.5425311203319502
812,29,74.7,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,339,White,Male,asymptomatic,others,failure,-108,57,0.33933933933933935
813,25,80.4,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,238,White,Male,asymptomatic,others,censoring,-183,-276,0.40337423312883436
814,37,83.9,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,20,White,Male,asymptomatic,ZDV only,censoring,-84,-25,0.6998689384010485
815,31,69.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,210,White,Male,asymptomatic,others,censoring,10,207,0.42599620493358636
816,38,75.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,118,White,Male,asymptomatic,others,censoring,7,-118,0.38548387096774195
817,42,74.6,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,742,Non-White,Male,symtomatic,ZDV only,failure,-97,-113,0.39276139410187666
818,35,94.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,96,White,Male,asymptomatic,others,failure,-10,-125,0.3452991452991453
819,27,78.5,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,476,White,Male,asymptomatic,ZDV only,censoring,-6,-233,0.5336597307221542
820,42,85.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,140,White,Male,asymptomatic,others,censoring,-106,-720,0.3045507584597433
821,28,68.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,185,White,Male,symtomatic,others,censoring,103,253,0.5
822,31,84.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1112,White,Male,asymptomatic,ZDV only,failure,-122,19,0.3168044077134986
823,31,78.9,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,338,-80,0.5380281690140845
824,31,72.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,773,White,Male,asymptomatic,others,failure,20,-214,0.19176706827309237
825,26,57.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-54,-424,0.2878787878787879
826,29,119.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,275,White,Male,asymptomatic,others,censoring,-33,-214,0.5093537414965986
827,26,79.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,334,White,Male,asymptomatic,ZDV only,censoring,-70,-377,0.36400817995910023
828,43,72.5,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,687,White,Male,symtomatic,others,censoring,51,62,0.22506393861892582
829,33,67.4,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,56,Non-White,Female,asymptomatic,ZDV only,failure,-90,-134,0.41388888888888886
830,48,77.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,307,White,Male,asymptomatic,others,censoring,99,154,0.7085889570552147
831,31,72.6,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-34,40,0.382172131147541
832,33,67.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,221,White,Male,asymptomatic,others,censoring,68,-143,0.615595075239398
833,31,64.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,918,White,Male,asymptomatic,others,censoring,23,-78,0.5253940455341506
834,26,71.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,2,White,Male,symtomatic,ZDV only,censoring,38,-166,0.3934659090909091
835,41,75.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,197,White,Male,asymptomatic,others,censoring,-69,-418,0.31314878892733566
836,29,71.7,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1138,White,Male,asymptomatic,others,censoring,-96,-110,0.5372907153729072
837,32,73.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,137,White,Male,asymptomatic,others,failure,19,109,0.24289405684754523
838,27,67.9,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,455,Non-White,Male,symtomatic,others,failure,33,280,0.309265944645006
839,39,86.0,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,88,1087,0.21148325358851675
840,35,76.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,213,White,Male,symtomatic,others,failure,-41,-270,0.2617680826636051
841,35,83.5,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,213,White,Female,symtomatic,ZDV only,censoring,-47,-67,0.5594594594594594
842,29,75.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,279,382,0.4178628389154705
843,34,74.9,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,61,37,0.3921259842519685
844,36,69.3,no hemophilia,homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,368,White,Male,asymptomatic,ZDV only,censoring,5,3,0.3182359952324195
845,41,76.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,517,White,Male,asymptomatic,others,censoring,43,-214,0.31022823330515636
846,36,67.5,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,91,White,Male,asymptomatic,others,censoring,66,77,0.36666666666666664
847,36,71.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,280,White,Male,asymptomatic,others,censoring,210,147,0.31785714285714284
848,38,70.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-52,-85,1.0
849,38,73.3,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,531,Non-White,Male,asymptomatic,others,censoring,12,-552,0.13024809160305342
850,32,85.8,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1116,White,Male,asymptomatic,others,censoring,27,-31,0.36486486486486486
851,37,45.6,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,432,White,Female,symtomatic,others,failure,-73,-30,0.4282115869017632
852,28,75.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,150,-29,0.3880597014925373
853,32,89.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1055,White,Male,asymptomatic,others,censoring,-32,-1210,0.10577644411102775
854,30,68.2,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,37,White,Male,symtomatic,others,failure,-147,-186,0.45875251509054327
855,39,65.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1423,White,Male,symtomatic,others,failure,15,-19,0.7911877394636015
856,39,68.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,885,White,Male,symtomatic,others,censoring,73,19,0.26040268456375837
857,33,78.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,242,-293,0.3076152304609218
858,31,87.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-36,-26,0.3793103448275862
859,31,60.1,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,693,White,Female,asymptomatic,others,censoring,82,95,0.3660287081339713
860,44,102.1,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,36,-179,0.30864197530864196
861,26,89.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,23,-259,0.21104536489151873
862,27,78.1,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,279,376,1.0512820512820513
863,35,87.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-70,9,0.7600574712643678
864,39,81.7,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,39,198,0.3484729835552075
865,27,81.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,56,-254,0.3460038986354776
866,35,85.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,83,-171,0.2788844621513944
867,24,90.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-57,-102,0.7448132780082988
868,31,79.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,55,37,0.7439353099730458
869,30,62.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,31,-652,0.20754716981132076
870,40,72.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,28,-156,0.29861849096705634
871,30,79.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,failure,-183,-428,0.3283018867924528
872,25,59.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,182,-408,0.2321867321867322
873,49,94.6,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-226,-486,0.4815668202764977
874,30,74.57184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,957,White,Male,asymptomatic,others,censoring,-32,-141,0.32797202797202796
875,36,69.31008,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,987,Non-White,Female,asymptomatic,ZDV only,censoring,321,392,0.356401384083045
876,31,78.9264,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1469,White,Male,asymptomatic,ZDV only,failure,-90,-534,0.38310269482884196
877,32,89.22312,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,986,White,Male,asymptomatic,others,censoring,67,115,0.3281710914454277
878,44,86.36544,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1339,White,Male,asymptomatic,others,censoring,-228,-543,0.3772357723577236
879,48,77.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1201,White,Male,asymptomatic,others,failure,-30,-240,0.22131147540983606
880,63,65.0916,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,965,White,Female,asymptomatic,others,censoring,21,187,0.44563918757467147
881,24,79.92432,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,988,White,Male,asymptomatic,others,censoring,-58,121,0.29834605597964375
882,39,80.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,986,Non-White,Male,asymptomatic,others,censoring,84,205,0.4499437570303712
883,29,81.37584,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,876,White,Male,asymptomatic,others,censoring,-39,-446,0.3863037752414399
884,29,71.442,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,175,White,Male,asymptomatic,ZDV only,censoring,54,56,0.6537267080745341
885,31,79.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,152,White,Male,asymptomatic,others,censoring,-62,-560,0.34487840825350036
886,33,58.10616,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,42,White,Female,asymptomatic,others,censoring,-27,23,0.666214382632293
887,31,57.3804,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,39,White,Female,asymptomatic,others,censoring,-13,34,0.5095715587967183
888,31,85.77576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,865,White,Male,asymptomatic,others,censoring,-36,160,0.3597640891218873
889,65,71.07912,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,10,26,0.5393401015228426
890,46,79.1532,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,949,White,Male,asymptomatic,ZDV only,censoring,-26,-23,0.15508824633871574
891,32,72.576,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,163,48,0.3548951048951049
892,30,83.50776,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-81,-409,0.3557874762808349
893,28,44.18064,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,5,-349,0.36830520909757886
894,25,84.1428,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,115,702,0.27789473684210525
895,26,63.504,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,813,White,Male,asymptomatic,others,censoring,-49,-341,0.2346688470973017
896,43,69.4008,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1000,Non-White,Male,symtomatic,others,failure,-48,343,0.0984647961884595
897,46,90.72,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,855,Non-White,Male,asymptomatic,ZDV only,censoring,2,-454,0.1509330406147091
898,29,69.4008,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1528,White,Male,asymptomatic,others,censoring,92,94,0.49800399201596807
899,28,83.32632,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,510,White,Male,asymptomatic,ZDV only,censoring,-68,-231,0.2963620230700976
900,26,82.1,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1231,White,Male,asymptomatic,others,censoring,24,101,0.32727272727272727
901,50,97.0704,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,957,White,Male,symtomatic,ZDV only,failure,-25,-122,0.39950980392156865
902,37,94.8024,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,732,White,Male,asymptomatic,ZDV only,censoring,-43,-23,0.4664778092540132
903,55,77.7924,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1146,Non-White,Male,asymptomatic,others,failure,-31,-445,0.14869888475836432
904,34,74.3904,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,985,White,Male,asymptomatic,others,censoring,159,-341,0.33582647718773373
905,31,58.8,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,764,Non-White,Male,symtomatic,ZDV only,failure,-37,-202,0.2475609756097561
906,48,82.3284,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,829,White,Male,asymptomatic,others,censoring,87,-80,0.5372168284789643
907,29,88.9056,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,132,1360,0.15873592444605886
908,36,71.8956,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,403,White,Male,symtomatic,others,failure,-102,-23,0.30148048452220727
909,43,77.112,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,433,White,Male,symtomatic,ZDV only,censoring,16,-181,0.29220138203356366
910,32,82.1016,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,108,95,0.2077922077922078
911,30,98.4312,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,355,47,0.594017094017094
912,36,73.0296,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,578,White,Male,symtomatic,others,censoring,48,3,0.3830049261083744
913,25,66.5,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,57,-235,0.5128205128205128
914,41,62.1432,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,103,Non-White,Male,asymptomatic,ZDV only,failure,24,355,0.6052631578947368
915,48,45.4,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,73,-9,0.8400770712909441
916,45,67.5864,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,494,White,Male,symtomatic,others,censoring,-54,3,1.0329113924050632
917,30,60.102,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,430,White,Male,asymptomatic,others,failure,3,-394,0.125193199381762
918,43,65.772,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,320,White,Female,symtomatic,others,censoring,195,161,0.4652605459057072
919,41,74.3904,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,111,Non-White,Female,asymptomatic,others,censoring,235,-30,0.6789250353606789
920,31,42.4116,no hemophilia,no homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,99,Non-White,Female,asymptomatic,others,censoring,-128,-19,0.5981308411214953
921,44,82.1016,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,749,White,Male,asymptomatic,ZDV only,censoring,39,278,0.36258278145695366
922,29,57.1536,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,68,Non-White,Female,asymptomatic,ZDV only,censoring,233,49,0.6213592233009708
923,43,69.4008,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,20,-277,0.3292134831460674
924,27,79.38,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,55,White,Male,asymptomatic,others,failure,-4,-339,0.189873417721519
925,28,92.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,38,Non-White,Male,asymptomatic,others,censoring,-31,-194,0.5179425837320574
926,39,45.8136,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,723,Non-White,Female,asymptomatic,others,censoring,149,-25,0.1641554321966693
927,35,97.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,585,Non-White,Male,asymptomatic,others,censoring,126,-39,0.4090909090909091
928,35,88.6788,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,27,112,0.37216828478964403
929,27,76.2048,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-18,-125,0.6023778071334214
930,26,57.834,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,failure,109,165,0.2202020202020202
931,36,63.0504,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,493,White,Male,asymptomatic,others,censoring,33,-51,0.3573529411764706
932,30,90.0396,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,106,Non-White,Male,asymptomatic,ZDV only,censoring,-22,-21,0.2623604465709729
933,26,63.6,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,104,80,0.6930022573363431
934,29,81.4212,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,77,-144,0.42995169082125606
935,57,57.1536,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,193,Non-White,Female,asymptomatic,others,failure,-235,-336,0.7556904400606981
936,41,63.0504,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,245,Non-White,Male,asymptomatic,others,censoring,102,32,0.5878378378378378
937,36,81.1944,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,115,-68,0.7135593220338983
938,45,78.9264,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,369,White,Male,asymptomatic,others,censoring,-38,-412,0.26933193056286164
939,40,75.2976,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,25,White,Male,asymptomatic,others,censoring,183,-296,0.3511326860841424
940,30,78.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,88,-182,0.40576923076923077
941,37,88.6788,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,15,-246,0.5966386554621849
942,39,73.0296,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,157,234,0.29697766097240474
943,27,53.16192,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,symtomatic,others,failure,57,-453,0.22682445759368836
944,26,77.112,no hemophilia,no homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-23,-646,0.07587119541243935
945,38,130.6368,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,9,-290,0.40569020021074814
946,29,79.38,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,66,-27,0.40993788819875776
947,30,83.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,184,-494,0.18568232662192394
948,49,59.1948,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,-11,-103,0.70276008492569
949,36,50.3496,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,331,-184,0.32677165354330706
950,17,51.2568,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,-134,-511,0.4492635024549918
951,47,72.3,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,447,White,Male,asymptomatic,others,censoring,254,866,0.4365904365904366
952,41,73.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,191,White,Male,asymptomatic,ZDV only,censoring,-37,-68,0.6671490593342981
953,55,76.6584,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1759,White,Male,asymptomatic,others,censoring,-7,45,0.3445692883895131
954,40,78.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,685,White,Male,asymptomatic,others,failure,90,413,0.41147540983606556
955,34,68.04,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,883,White,Male,asymptomatic,others,failure,-174,-34,0.47181372549019607
956,31,57.6072,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,116,-94,0.8125
957,46,62.23392,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1218,White,Male,asymptomatic,others,censoring,-98,-235,0.37751004016064255
958,31,68.04,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1147,White,Male,asymptomatic,others,censoring,182,206,0.36223929747530187
959,34,72.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,225,Non-White,Male,asymptomatic,others,censoring,78,22,0.2809667673716012
960,22,77.112,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1051,White,Male,asymptomatic,ZDV only,censoring,-140,-601,0.2810810810810811
961,33,75.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,915,White,Male,asymptomatic,others,censoring,-74,-114,0.39301700984780663
962,29,68.9472,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,57,Non-White,Female,asymptomatic,others,censoring,130,174,0.6359516616314199
963,37,70.7616,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,146,335,0.33495145631067963
964,45,82.782,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,135,198,0.5737051792828686
965,36,66.2256,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,307,Non-White,Female,symtomatic,others,censoring,-46,-35,0.6
966,29,69.4008,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,893,White,Female,symtomatic,ZDV only,failure,-83,-123,0.4354243542435424
967,37,74.3904,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,145,Non-White,Male,asymptomatic,others,censoring,-76,-283,0.23914699162223915
968,22,105.6888,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,failure,-109,-142,0.3668407310704961
969,56,82.1016,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,142,-150,0.8863198458574181
970,39,85.2768,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,295,676,0.656934306569343
971,25,48.3084,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,-193,-211,0.5394736842105263
972,56,71.2152,no hemophilia,no homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,858,Non-White,Male,asymptomatic,others,censoring,305,280,0.4411384217335058
973,29,71.8,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,161,Non-White,Male,asymptomatic,others,censoring,-25,-241,0.4994786235662148
974,35,77.7,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,248,Non-White,Male,asymptomatic,ZDV only,censoring,31,-136,0.3223062381852552
975,36,75.4,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,127,White,Male,asymptomatic,ZDV only,failure,76,-252,0.37299338999055714
976,37,63.6,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,111,429,0.38847858197932056
977,44,84.3696,no hemophilia,homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1137,Non-White,Male,asymptomatic,others,censoring,72,398,0.3451923076923077
978,49,115.668,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,19,-911,0.2463768115942029
979,45,69.8544,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,4,Non-White,Male,asymptomatic,others,censoring,-96,-288,0.4766734279918864
980,50,65.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,13,-408,0.28553379658875555
981,35,81.1,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,551,White,Male,asymptomatic,others,failure,33,157,0.12482065997130559
982,29,88.6,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,254,789,0.22713687985654513
983,38,83.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,139,446,0.6666666666666666
984,28,62.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,68,White,Male,asymptomatic,others,censoring,87,-134,0.23789473684210527
985,32,73.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-58,-51,0.39269813000890474
986,30,77.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,357,304,0.38337468982630274
987,49,76.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-101,-1357,0.1448961937716263
988,47,93.2,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,405,Non-White,Male,asymptomatic,ZDV only,censoring,-59,208,0.7
989,39,110.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,109,White,Male,asymptomatic,others,censoring,55,167,0.15151515151515152
990,59,58.6,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,763,Non-White,Female,asymptomatic,others,censoring,29,-10,0.3045822102425876
991,38,49.8,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,354,Non-White,Female,asymptomatic,ZDV only,censoring,19,432,0.4484924623115578
992,62,95.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1798,Non-White,Male,asymptomatic,ZDV only,censoring,-5,295,0.4629032258064516
993,42,65.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,340,Non-White,Male,asymptomatic,others,failure,27,328,0.3515509601181684
994,33,73.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,27,148,0.8854961832061069
995,29,61.4,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,335,Non-White,Female,asymptomatic,ZDV only,censoring,-8,161,0.25396825396825395
996,32,92.7,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,304,White,Male,asymptomatic,others,failure,47,-27,0.40476190476190477
997,44,77.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,148,-77,0.6944099378881987
998,37,59.1,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,failure,39,42,0.41359223300970877
999,32,71.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,154,White,Male,asymptomatic,others,failure,130,294,0.2903225806451613
1000,39,80.9,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1265,Non-White,Female,asymptomatic,others,censoring,-28,-207,0.42857142857142855
1001,38,82.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,19,-308,0.2253922967189729
1002,35,62.3,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,493,Non-White,Female,asymptomatic,others,censoring,-1,-123,0.4796650717703349
1003,31,70.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,365,Non-White,Female,asymptomatic,others,censoring,-19,161,0.3711747285291214
1004,43,70.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,28,-607,0.22396114409066378
1005,31,86.8,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,122,-214,0.28865979381443296
1006,35,79.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,142,Non-White,Male,asymptomatic,others,censoring,-54,-143,0.27958993476234856
1007,32,86.184,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,304,White,Male,asymptomatic,ZDV only,censoring,-21,216,0.5206043956043956
1008,27,57.6072,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,945,White,Male,symtomatic,others,censoring,-86,-396,0.292258064516129
1009,33,71.6688,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,838,White,Male,symtomatic,others,failure,-61,-16,0.3488372093023256
1010,32,100.6992,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,213,White,Male,symtomatic,ZDV only,censoring,-32,-108,0.3647859922178988
1011,30,80.7408,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,19,-414,0.2870848708487085
1012,31,102.06,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,307,White,Male,asymptomatic,ZDV only,censoring,-4,16,0.4212218649517685
1013,45,71.6688,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,875,White,Male,asymptomatic,others,censoring,201,-52,0.2728522336769759
1014,33,67.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,failure,-141,-386,0.1817562968005446
1015,36,58.0608,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,855,Non-White,Female,asymptomatic,others,censoring,-184,-516,0.27827502034174123
1016,39,98.4312,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,120,-122,0.28751753155680226
1017,36,84.3696,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,6,-46,0.2874902874902875
1018,36,86.184,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1111,White,Male,asymptomatic,others,censoring,-68,-442,0.38099630996309963
1019,25,67.5864,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,365,White,Male,symtomatic,others,failure,9,129,0.20868347338935575
1020,47,95.2,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,730,White,Male,symtomatic,others,failure,-32,-258,0.09097421203438395
1021,44,82.1016,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,602,White,Male,asymptomatic,others,censoring,94,82,0.38073807380738073
1022,40,79.38,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,31,White,Male,asymptomatic,others,censoring,90,220,0.1918489065606362
1023,37,85.7304,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-9,54,0.36102564102564105
1024,32,76.6584,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,31,White,Male,asymptomatic,others,censoring,-53,-576,0.1715686274509804
1025,30,70.7616,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,failure,-140,-591,0.21920529801324504
1026,47,85.2768,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,182,75,0.500875656742557
1027,36,84.3696,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-27,-272,0.18306636155606407
1028,39,78.4728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,18,49,0.366869918699187
1029,35,73.9368,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,879,Non-White,Female,asymptomatic,ZDV only,failure,25,-382,0.1881625441696113
1030,24,61.236,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-114,-134,0.1998551774076756
1031,33,66.6792,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,252,-223,0.3066546762589928
1032,42,103.4208,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,167,85,0.726027397260274
1033,38,76.2048,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,96,193,0.2814710042432815
1034,29,64.4112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1668,Non-White,Male,asymptomatic,others,censoring,121,296,0.5084306095979247
1035,47,71.2152,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,67,Non-White,Female,asymptomatic,others,censoring,102,114,0.35294117647058826
1036,42,69.8544,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,230,Non-White,Female,asymptomatic,others,censoring,39,-347,0.33859510655090763
1037,31,80.2872,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,238,Non-White,Male,asymptomatic,others,censoring,-46,-243,0.3502415458937198
1038,37,69.8544,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,650,Non-White,Female,asymptomatic,ZDV only,censoring,27,90,0.788135593220339
1039,42,67.1328,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,822,White,Female,asymptomatic,others,censoring,-45,-330,0.3730769230769231
1040,34,61.6896,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,249,Non-White,Female,asymptomatic,others,censoring,-46,258,0.2515274949083503
1041,42,86.8644,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,25,Non-White,Female,symtomatic,ZDV only,failure,-23,-51,0.4689922480620155
1042,29,58.2876,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,959,Non-White,Female,asymptomatic,others,censoring,-44,1,0.4544179523141655
1043,30,70.7616,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,230,White,Female,asymptomatic,ZDV only,censoring,-46,-19,1.0267062314540059
1044,27,59.4216,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,146,409,0.4578005115089514
1045,34,100.3,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1019,White,Male,asymptomatic,others,censoring,5,-107,0.7314629258517034
1046,37,63.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,768,Non-White,Female,asymptomatic,ZDV only,censoring,-75,-208,0.1755629691409508
1047,31,41.0,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1027,White,Female,asymptomatic,others,censoring,-384,-570,0.6181818181818182
1048,40,72.7,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,668,White,Female,symtomatic,others,censoring,166,234,0.442090395480226
1049,30,79.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1633,Non-White,Male,asymptomatic,others,censoring,-2,-34,0.15369522563767168
1050,31,69.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,402,Non-White,Female,asymptomatic,others,censoring,-86,-208,0.6090604026845637
1051,32,77.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,847,Non-White,Female,asymptomatic,others,censoring,148,140,0.30866425992779783
1052,34,61.2,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,329,Non-White,Female,asymptomatic,ZDV only,failure,-77,-114,0.23581757508342602
1053,33,68.0,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,842,White,Male,asymptomatic,ZDV only,censoring,-40,-83,0.4810126582278481
1054,38,95.5,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,909,Non-White,Male,asymptomatic,others,censoring,-53,-103,0.3221003134796238
1055,45,69.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,329,Non-White,Female,asymptomatic,ZDV only,censoring,21,-65,0.2671232876712329
1056,37,69.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,failure,42,-112,0.32006125574272587
1057,24,60.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,359,Non-White,Female,asymptomatic,others,censoring,-55,-64,0.5192307692307693
1058,26,67.6,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,54,-89,0.64
1059,33,43.8,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,52,-58,0.8622950819672132
1060,39,127.7,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,49,-70,0.5955451348182884
1061,31,58.0608,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,-109,-199,0.6170839469808542
1062,38,70.7616,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1673,White,Male,asymptomatic,others,censoring,-32,-200,0.44273743016759776
1063,34,55.3392,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1635,White,Female,asymptomatic,ZDV only,censoring,-1,39,0.5418006430868167
1064,41,61.236,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,195,Non-White,Female,asymptomatic,ZDV only,censoring,-45,-147,0.7599337748344371
1065,45,58.5144,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1651,Non-White,Female,asymptomatic,others,censoring,-25,-61,0.5842880523731587
1066,33,57.1536,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1420,Non-White,Female,asymptomatic,others,censoring,26,-40,0.7794612794612794
1067,45,64.4112,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1583,Non-White,Female,asymptomatic,others,failure,0,19,0.22941176470588234
1068,50,53.5248,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1648,Non-White,Female,asymptomatic,others,censoring,-109,-459,0.5095338983050848
1069,40,71.6688,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,59,-140,0.8924949290060852
1070,42,73.0296,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,676,White,Male,asymptomatic,others,censoring,139,192,0.43672014260249553
1071,31,57.6072,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1356,Non-White,Female,asymptomatic,others,censoring,35,41,1.0454545454545454
1072,52,55.3392,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1439,Non-White,Female,asymptomatic,others,censoring,-63,-189,0.44254937163375224
1073,41,76.2048,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,289,Non-White,Male,asymptomatic,others,censoring,-56,-25,0.375
1074,22,47.628,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,200,Non-White,Female,asymptomatic,others,censoring,16,-131,0.40725806451612906
1075,29,45.8136,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,671,Non-White,Female,asymptomatic,others,censoring,30,40,0.31684491978609625
1076,33,79.8336,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,436,Non-White,Female,asymptomatic,others,censoring,30,-256,0.25394896719319565
1077,36,80.7408,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,failure,80,217,0.20953326713008938
1078,20,84.8232,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,152,-303,0.3112094395280236
1079,37,58.5144,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,65,-13,0.551980198019802
1080,39,100.4724,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,96,13,0.4439461883408072
1081,35,63.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1272,White,Male,asymptomatic,others,censoring,7,-290,0.5346153846153846
1082,38,74.3904,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,374,White,Male,asymptomatic,others,failure,-16,-305,0.08229988726042842
1083,38,88.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,355,White,Male,asymptomatic,others,censoring,-41,139,0.31232876712328766
1084,30,149.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-193,-292,0.3279467680608365
1085,35,60.3288,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,665,White,Male,symtomatic,others,censoring,-20,-465,0.2574002574002574
1086,31,72.1224,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,807,White,Male,asymptomatic,ZDV only,failure,-83,-306,0.39238263950398583
1087,45,68.4936,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,818,White,Male,asymptomatic,others,censoring,67,-4,0.37059724349157736
1088,41,71.442,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,802,White,Male,asymptomatic,others,censoring,116,-261,0.14886285320468642
1089,41,69.4008,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,739,Non-White,Male,asymptomatic,others,censoring,134,83,0.4892086330935252
1090,40,74.3904,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,782,White,Male,asymptomatic,others,censoring,70,-218,0.3395585738539898
1091,34,61.6896,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,930,Non-White,Male,asymptomatic,others,censoring,-51,-457,0.25
1092,32,73.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,902,White,Male,symtomatic,others,failure,66,-586,0.1735052754982415
1093,38,89.3592,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,792,White,Male,symtomatic,others,failure,-37,-42,0.6209964412811388
1094,35,66.6792,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1232,White,Male,asymptomatic,ZDV only,censoring,38,10,0.4183109707971586
1095,44,83.916,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,793,White,Male,asymptomatic,ZDV only,censoring,4,-53,0.5689001264222503
1096,35,75.978,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,869,Non-White,Male,asymptomatic,others,censoring,-105,-32,0.415124698310539
1097,47,64.638,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1360,White,Male,asymptomatic,others,failure,-97,-208,0.5
1098,37,89.04168,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,882,White,Male,asymptomatic,others,censoring,88,-187,0.3336229365768897
1099,26,67.5864,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,792,White,Male,asymptomatic,others,censoring,121,237,0.6983695652173914
1100,31,69.4008,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,30,Non-White,Male,asymptomatic,others,censoring,-77,-123,0.5383580080753702
1101,41,69.4008,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,168,White,Male,symtomatic,others,failure,7,-91,0.16666666666666666
1102,39,81.648,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,482,White,Male,asymptomatic,others,censoring,-142,-332,0.22744599745870395
1103,29,53.0712,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-77,441,0.46131528046421666
1104,62,76.4316,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-151,-148,0.29310344827586204
1105,33,60.7824,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,497,Non-White,Male,symtomatic,ZDV only,censoring,-127,-628,0.26244343891402716
1106,30,89.8128,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,793,White,Male,asymptomatic,ZDV only,failure,-114,-418,0.21449704142011836
1107,36,66.6792,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,728,White,Female,symtomatic,ZDV only,failure,-54,9,0.29109947643979056
1108,49,91.1736,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,32,-549,0.2321178120617111
1109,33,67.8132,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,60,-10,0.7240143369175627
1110,32,70.7616,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,265,334,0.3858185610010427
1111,42,93.4416,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,372,White,Male,symtomatic,others,censoring,-33,153,0.7206703910614525
1112,24,71.6688,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-51,166,0.34896810506566606
1113,49,82.1016,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,480,White,Male,asymptomatic,ZDV only,failure,-179,-434,0.18905693950177935
1114,55,83.4624,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,168,White,Male,asymptomatic,ZDV only,failure,-65,199,0.312
1115,37,76.4316,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,298,White,Male,asymptomatic,ZDV only,failure,88,202,0.5597548518896833
1116,27,65.3184,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,460,White,Male,asymptomatic,others,censoring,-32,243,0.5288640595903166
1117,31,86.6376,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,333,White,Male,asymptomatic,ZDV only,failure,-43,-24,0.2757234726688103
1118,39,96.1632,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,268,314,0.40294117647058825
1119,53,97.524,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,132,-330,0.2786885245901639
1120,42,91.6272,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,72,-12,0.24203273040482343
1121,54,60.7824,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,178,White,Male,asymptomatic,others,failure,-89,-351,0.2
1122,20,72.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,21,White,Male,asymptomatic,ZDV only,censoring,51,142,0.40778097982708933
1123,26,69.4008,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,272,Non-White,Male,asymptomatic,others,censoring,15,125,0.3103448275862069
1124,30,53.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,302,White,Male,symtomatic,others,failure,-54,300,0.6808009422850412
1125,31,81.8748,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-57,-21,0.5205882352941177
1126,30,82.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,85,Non-White,Male,asymptomatic,others,censoring,0,211,0.4348355663824604
1127,32,83.2,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,7,Non-White,Male,asymptomatic,ZDV only,failure,-126,-789,0.1872
1128,31,75.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,11,-30,0.8181818181818182
1129,29,65.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,367,Non-White,Male,asymptomatic,others,censoring,-11,-98,0.5112692763938316
1130,30,64.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,45,White,Male,symtomatic,others,failure,-58,-39,0.42016806722689076
1131,23,85.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,1,4,0.9285714285714286
1132,33,80.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,679,Non-White,Male,asymptomatic,others,censoring,34,-97,0.603399433427762
1133,30,72.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,539,White,Male,asymptomatic,others,censoring,49,394,0.22088068181818182
1134,27,62.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,149,Non-White,Male,asymptomatic,others,censoring,202,244,0.42376681614349776
1135,27,75.8,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-250,-132,0.749727965179543
1136,37,78.9264,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,66,-88,0.595360824742268
1137,27,87.318,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-90,-345,0.5714285714285714
1138,37,92.5344,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,205,52,0.33986175115207373
1139,20,67.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,86,White,Male,asymptomatic,others,censoring,-28,-57,0.7296195652173914
1140,29,78.4728,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,20,-77,0.3328488372093023
1141,37,78.0192,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,152,White,Male,symtomatic,others,failure,-176,-480,0.2498373454782043
1142,30,81.8748,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,20,-65,0.36197718631178705
1143,33,80.514,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,90,Non-White,Male,asymptomatic,others,censoring,119,166,0.156289707750953
1144,33,76.2048,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-634,-161,2.355599214145383
1145,37,76.6584,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,51,34,0.29295774647887324
1146,26,65.3184,hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,20,69,0.6511627906976745
1147,30,81.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,32,-679,0.24274099883855982
1148,23,78.4728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,238,White,Male,asymptomatic,others,censoring,78,702,0.328125
1149,69,81.648,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,111,-996,0.20532490974729242
1150,46,76.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-32,-331,0.40717488789237666
1151,36,65.772,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,155,White,Female,asymptomatic,others,failure,-37,-315,0.5423242467718795
1152,19,50.8032,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,-31,-89,0.6742081447963801
1153,28,78.9264,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,-164,-299,0.6675461741424802
1154,29,69.8544,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,5,White,Male,asymptomatic,ZDV only,censoring,33,-119,0.45
1155,29,100.6992,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,-118,-392,0.5746421267893661
1156,34,68.4936,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,240,766,0.2654754307594129
1157,48,69.8544,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-68,-67,0.4178302900107411
1158,27,86.184,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,34,161,0.1576923076923077
1159,70,63.0504,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,95,-182,0.7023460410557185
1160,28,80.2872,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-42,-174,0.39268121041520054
1161,28,65.772,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-44,-556,0.261478163493841
1162,27,62.5968,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-28,66,0.29443838604143946
1163,36,77.112,hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,14,-299,0.33988212180746563
1164,42,73.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1224,White,Male,symtomatic,others,failure,-64,-405,0.31078610603290674
1165,55,71.2152,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,89,Non-White,Male,asymptomatic,ZDV only,censoring,-69,46,0.5957446808510638
1166,44,69.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,933,White,Male,asymptomatic,others,censoring,-43,-721,0.2216278181123424
1167,30,57.6072,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1003,White,Female,asymptomatic,ZDV only,censoring,-30,50,1.0566037735849056
1168,41,72.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,228,326,0.23509933774834438
1169,43,64.4112,no hemophilia,homosexual,no IV drugs use,70%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,29,White,Male,symtomatic,others,failure,-112,-17,0.17372881355932204
1170,38,78.4728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,88,White,Male,asymptomatic,others,censoring,-43,-57,0.5515463917525774
1171,32,72.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,113,White,Male,asymptomatic,others,censoring,9,126,0.44731610337972166
1172,48,112.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,548,White,Female,asymptomatic,ZDV only,failure,48,605,0.17342657342657342
1173,40,66.3,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,382,Non-White,Male,asymptomatic,others,censoring,232,371,0.3709981167608286
1174,39,91.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,178,White,Male,asymptomatic,others,censoring,-258,-603,0.48050036791758644
1175,35,73.71,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,45,41,0.3979763912310287
1176,38,50.0,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,failure,240,415,0.29069767441860467
1177,30,129.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,33,22,0.24348534201954397
1178,29,61.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,382,Non-White,Male,asymptomatic,ZDV only,censoring,21,262,0.4938461538461538
1179,41,58.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,210,-4,0.37341772151898733
1180,36,69.5,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,799,White,Female,asymptomatic,others,failure,-37,46,0.8113207547169812
1181,36,65.9,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,503,Non-White,Male,asymptomatic,others,censoring,146,123,0.2578890097932535
1182,32,63.6,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,353,White,Female,asymptomatic,others,censoring,198,414,0.9136212624584718
1183,28,63.6,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,728,Non-White,Male,asymptomatic,ZDV only,censoring,7,208,0.37031900138696255
1184,35,59.1,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,33,White,Female,asymptomatic,others,censoring,233,-127,0.4418918918918919
1185,42,72.576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-95,-110,0.375743162901308
1186,38,55.7928,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,770,White,Female,asymptomatic,others,censoring,-245,-243,0.7046783625730995
1187,35,62.1432,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,322,330,0.7009345794392523
1188,29,66.6792,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,93,-32,0.3647959183673469
1189,35,99.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,101,-659,0.2078125
1190,36,62.7,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,23,-700,0.426479949077021
1191,36,78.246,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-136,87,0.5121621621621621
1192,45,70.9,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,-21,-40,0.6270430906389302
1193,27,75.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-169,-271,0.5735632183908046
1194,37,78.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-13,-98,0.6581059390048154
1195,42,61.236,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1253,White,Male,symtomatic,ZDV only,censoring,-128,-137,0.5003891050583658
1196,34,63.59472,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1356,White,Male,symtomatic,ZDV only,censoring,-151,-281,0.32737430167597764
1197,43,61.236,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1420,White,Male,asymptomatic,others,censoring,39,-34,0.4750830564784053
1198,29,74.844,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,889,White,Male,symtomatic,ZDV only,failure,49,79,0.5607638888888888
1199,40,88.9056,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,804,White,Male,asymptomatic,ZDV only,failure,123,625,0.13326168726491133
1200,34,57.6072,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1292,White,Male,symtomatic,others,censoring,207,434,0.5263157894736842
1201,45,86.184,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1594,White,Male,symtomatic,others,failure,5,80,0.44387755102040816
1202,33,89.3592,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,925,White,Male,symtomatic,others,censoring,127,316,0.16695352839931152
1203,34,64.4112,no hemophilia,homosexual,no IV drugs use,70%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,930,White,Male,asymptomatic,ZDV only,censoring,20,-144,0.31650135256988277
1204,32,74.844,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1475,White,Male,asymptomatic,others,censoring,278,487,0.48787061994609165
1205,48,71.8956,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,370,White,Male,asymptomatic,others,censoring,71,-19,0.36153846153846153
1206,38,64.4112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,917,White,Male,asymptomatic,others,failure,-44,277,0.3804347826086957
1207,45,73.0296,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1113,White,Male,asymptomatic,others,failure,-72,79,0.31275303643724695
1208,45,86.6376,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,192,37,0.49940968122786306
1209,42,62.5968,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,768,White,Male,asymptomatic,ZDV only,failure,-89,58,0.22611850060459493
1210,33,72.48528,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,75,White,Male,asymptomatic,others,censoring,92,-192,0.4163934426229508
1211,30,69.8544,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,167,White,Female,symtomatic,others,censoring,30,37,0.30413223140495865
1212,34,68.4936,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,796,White,Female,symtomatic,others,censoring,-5,-182,0.47404371584699456
1213,43,71.8956,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,686,White,Male,asymptomatic,others,censoring,-82,-148,0.381646030589949
1214,35,90.9468,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,630,White,Male,symtomatic,others,failure,84,275,0.42528735632183906
1215,29,73.71,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,33,Non-White,Male,symtomatic,others,failure,-55,79,0.3516068052930057
1216,32,78.4728,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-39,4,0.534965034965035
1217,54,73.2564,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,10,-188,0.3284848484848485
1218,42,70.308,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,857,White,Male,symtomatic,others,failure,-48,-110,0.2766990291262136
1219,34,76.8852,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,206,-479,0.15384615384615385
1220,23,53.9784,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,816,White,Male,asymptomatic,others,failure,-37,-308,0.24557260920897284
1221,35,67.5864,no hemophilia,no homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,755,Non-White,Female,asymptomatic,others,censoring,-54,-169,0.47176684881602915
1222,30,85.2768,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,108,White,Male,symtomatic,others,censoring,51,58,0.5216049382716049
1223,40,73.0296,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,650,Non-White,Male,asymptomatic,others,failure,21,249,0.28055077452667815
1224,32,77.112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,24,White,Male,symtomatic,others,censoring,105,330,0.6156405990016639
1225,26,68.9472,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,561,White,Male,asymptomatic,ZDV only,failure,-136,-432,0.25
1226,42,71.6688,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,failure,66,115,0.28892455858747995
1227,38,82.3284,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,287,White,Male,asymptomatic,others,censoring,99,-211,0.7420965058236273
1228,26,76.6584,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-9,25,0.6910112359550562
1229,35,87.0912,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,795,Non-White,Male,symtomatic,ZDV only,censoring,-80,-180,0.5642201834862385
1230,33,78.6996,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,188,White,Male,symtomatic,others,censoring,109,-47,0.2624390243902439
1231,27,81.78408,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,234,106,0.5316027088036117
1232,39,63.9576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,54,209,0.4892703862660944
1233,48,82.5552,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,678,White,Male,asymptomatic,others,censoring,136,1063,0.14889918887601392
1234,38,77.7924,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,629,White,Male,symtomatic,others,censoring,95,-9,0.43386243386243384
1235,40,92.5344,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1169,White,Male,asymptomatic,others,censoring,50,108,0.4444444444444444
1236,26,92.0808,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,333,1436,0.1902587519025875
1237,44,66.2256,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,35,-171,0.35688405797101447
1238,29,65.3184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,154,20,0.7777777777777778
1239,37,82.782,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,114,284,0.5851063829787234
1240,28,81.1944,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,121,-208,0.4004329004329004
1241,45,63.0504,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,66,308,0.23669923995656894
1242,46,54.8856,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,304,White,Male,symtomatic,others,censoring,99,177,0.5216216216216216
1243,26,90.72,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,741,Non-White,Female,symtomatic,others,censoring,162,-20,0.5310519645120405
1244,21,112.4928,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,5,29,0.2907153729071537
1245,24,102.06,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,138,Non-White,Male,asymptomatic,others,censoring,35,-71,0.2647058823529412
1246,34,91.1736,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,46,White,Male,asymptomatic,others,failure,-32,481,0.1667864845434939
1247,27,97.9776,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,934,White,Female,symtomatic,ZDV only,failure,-49,125,0.47890818858560796
1248,27,70.7616,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,289,White,Male,asymptomatic,others,censoring,24,-218,0.4823529411764706
1249,29,86.72832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,20,White,Male,asymptomatic,others,censoring,85,350,0.19089316987740806
1250,52,90.58392,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,103,White,Male,asymptomatic,ZDV only,censoring,51,120,0.5
1251,29,78.0192,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,128,102,0.36046511627906974
1252,26,68.04,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,930,White,Male,asymptomatic,others,censoring,140,396,0.31543624161073824
1253,28,78.4728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,73,-190,0.4341164453524004
1254,36,74.3904,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,381,White,Male,symtomatic,ZDV only,failure,-13,-75,0.23895027624309392
1255,32,80.7408,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,43,-67,0.35846030473135526
1256,43,91.6272,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,10,-51,0.19080459770114944
1257,38,68.4936,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,370,Non-White,Female,asymptomatic,ZDV only,failure,4,419,0.14842578710644677
1258,35,100.6992,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,172,269,0.4036458333333333
1259,35,78.0192,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,149,167,0.3068920676202861
1260,28,59.10408,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1166,White,Female,asymptomatic,others,censoring,34,1,0.744807121661721
1261,23,66.906,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,53,-264,0.2203525641025641
1262,26,95.256,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,78,-202,0.3165322580645161
1263,34,100.6992,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,64,-603,0.2857954545454545
1264,33,84.8232,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,141,-53,0.3194192377495463
1265,32,84.8232,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,failure,60,610,0.2321285140562249
1266,30,77.5656,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,9,-433,0.3395604395604396
1267,24,70.7616,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-37,63,0.6158415841584158
1268,34,68.9472,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-16,-216,0.3090909090909091
1269,41,83.4624,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,83,331,0.10650887573964497
1270,34,58.0608,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,failure,212,300,0.27858439201451907
1271,41,83.916,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,94,White,Male,asymptomatic,ZDV only,failure,-87,18,0.30605285592497866
1272,44,100.2456,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,245,White,Female,asymptomatic,others,censoring,50,269,0.4445843828715365
1273,33,77.8,hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,928,White,Male,asymptomatic,others,censoring,22,-146,0.45454545454545453
1274,48,76.6584,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,210,Non-White,Male,asymptomatic,others,failure,-121,-229,0.3620689655172414
1275,36,83.6892,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,80,-228,0.23707533234859676
1276,29,59.8752,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,344,White,Female,asymptomatic,ZDV only,censoring,-134,-105,0.623015873015873
1277,28,59.8752,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-1,51,0.5509736540664376
1278,33,69.4008,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,233,White,Male,asymptomatic,others,censoring,-53,-561,0.2923076923076923
1279,35,76.4316,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-92,-126,0.625139043381535
1280,42,78.0192,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,-168,-128,0.44851657940663175
1281,26,80.7408,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-45,-2,0.30520909757887016
1282,42,81.648,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,722,White,Male,asymptomatic,others,censoring,-53,-280,0.17159763313609466
1283,28,69.4008,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,288,Non-White,Female,asymptomatic,others,failure,-46,-257,0.24115755627009647
1284,41,63.9576,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,432,White,Male,symtomatic,others,censoring,61,103,0.16947723440134907
1285,35,81.648,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,111,White,Male,asymptomatic,others,censoring,-74,229,0.5962219598583235
1286,47,86.6376,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,195,White,Male,symtomatic,others,censoring,-82,-209,0.3333333333333333
1287,33,71.6688,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,293,Non-White,Male,asymptomatic,others,censoring,-93,-346,0.37949101796407186
1288,23,73.71,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,82,White,Female,asymptomatic,others,censoring,-9,-96,0.6795212765957447
1289,36,56.2464,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1938,White,Male,symtomatic,ZDV only,censoring,60,-145,0.33808437856328394
1290,32,68.9472,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1308,White,Male,asymptomatic,ZDV only,failure,-88,-2,0.7560386473429952
1291,31,73.4832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,997,White,Male,symtomatic,others,censoring,80,280,0.3604309500489716
1292,44,67.1328,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,690,White,Male,symtomatic,others,failure,-91,-49,0.4441340782122905
1293,32,71.2152,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,991,White,Male,asymptomatic,others,censoring,-50,99,0.5648769574944071
1294,34,68.2668,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,980,White,Male,asymptomatic,others,failure,-134,-303,0.21247113163972287
1295,43,73.0296,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1270,White,Male,asymptomatic,ZDV only,failure,-336,-279,0.3112278397898884
1296,32,75.7512,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,975,White,Male,symtomatic,ZDV only,failure,-65,104,0.6887871853546911
1297,39,65.0916,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,983,White,Male,symtomatic,others,failure,-8,-776,0.13505154639175257
1298,28,103.4208,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,949,White,Male,asymptomatic,others,censoring,84,65,0.48110599078341015
1299,29,52.6176,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,781,Non-White,Female,asymptomatic,others,censoring,228,87,0.45434298440979953
1300,41,73.0296,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1110,White,Male,symtomatic,others,censoring,-63,-747,0.14866760168302945
1301,35,52.3908,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,187,53,0.9657258064516129
1302,51,68.9472,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,140,120,1.8770491803278688
1303,67,82.1016,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-4,54,0.3894736842105263
1304,27,55.3392,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,273,Non-White,Female,symtomatic,others,censoring,59,180,0.25
1305,31,89.3592,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-113,-445,0.42832909245122985
1306,45,89.8128,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,-93,-126,0.5455665024630542
1307,33,78.0192,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,36,White,Male,symtomatic,others,failure,-101,-78,0.44630071599045346
1308,27,64.4112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,21,White,Male,asymptomatic,others,censoring,-5,-294,0.42550143266475643
1309,26,55.566,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,342,White,Female,asymptomatic,others,censoring,117,1,0.4817320703653586
1310,26,82.1016,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,228,140,0.32210109018830524
1311,49,80.7408,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,18,639,0.2503192848020434
1312,36,78.9264,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-98,-189,0.3699788583509514
1313,39,89.3592,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,28,White,Male,asymptomatic,ZDV only,failure,-212,-979,0.28075916230366493
1314,32,69.8544,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-160,122,0.6671899529042387
1315,44,95.256,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,34,-506,0.376844494892168
1316,30,64.638,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,122,269,0.5770925110132159
1317,26,91.6272,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,88,121,0.48964677222898906
1318,35,70.7616,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,12,275,0.5100117785630153
1319,42,79.8336,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,34,-275,0.4142857142857143
1320,45,78.0192,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,101,209,0.30778894472361806
1321,49,67.1328,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,-54,-697,0.23550724637681159
1322,27,86.6376,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,937,White,Male,asymptomatic,others,failure,-50,-440,0.18518518518518517
1323,33,76.2048,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,626,White,Male,asymptomatic,ZDV only,censoring,50,-550,0.13618677042801555
1324,27,67.5864,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,770,White,Male,asymptomatic,others,censoring,10,50,0.5555555555555556
1325,40,75.7512,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,923,White,Male,asymptomatic,others,censoring,-140,-50,0.975
1326,26,112.4928,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,931,Non-White,Female,asymptomatic,ZDV only,failure,-40,-80,0.2753623188405797
1327,39,79.1,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,778,Non-White,Female,asymptomatic,others,censoring,-20,-280,0.39080459770114945
1328,29,68.4936,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1026,White,Male,asymptomatic,ZDV only,failure,10,-180,0.345679012345679
1329,34,92.7612,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1107,White,Male,asymptomatic,others,censoring,130,-200,0.43548387096774194
1330,36,66.6792,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,943,White,Male,asymptomatic,ZDV only,censoring,0,-120,0.2702702702702703
1331,21,65.5452,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1148,White,Male,asymptomatic,others,censoring,230,-350,0.28888888888888886
1332,25,69.8544,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,947,White,Male,asymptomatic,others,censoring,32,-147,0.2997076023391813
1333,30,59.6484,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,922,White,Male,asymptomatic,others,censoring,170,110,0.31
1334,38,66.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,959,White,Male,asymptomatic,others,censoring,170,-110,0.3918918918918919
1335,54,74.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,959,White,Male,symtomatic,ZDV only,failure,-160,-470,0.38016528925619836
1336,35,68.04,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,922,Non-White,Male,asymptomatic,others,failure,90,280,0.39655172413793105
1337,46,73.0296,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,925,White,Male,asymptomatic,others,censoring,50,-430,0.18666666666666668
1338,35,77.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,427,White,Male,symtomatic,ZDV only,censoring,20,-310,0.4336283185840708
1339,35,78.246,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,574,White,Male,asymptomatic,others,censoring,70,-80,0.367816091954023
1340,28,76.6584,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,130,-480,0.36363636363636365
1341,49,86.184,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,210,-90,0.45454545454545453
1342,34,76.2048,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-40,0,0.6702127659574468
1343,30,76.2048,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-90,-360,0.8
1344,56,46.8,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,137,Non-White,Female,asymptomatic,others,censoring,30,-200,0.3372093023255814
1345,40,85.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,190,-60,0.4935064935064935
1346,41,77.7,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,60,-260,0.3277310924369748
1347,22,67.5864,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,34,Non-White,Female,asymptomatic,ZDV only,censoring,-140,70,0.7358490566037735
1348,44,72.1224,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,200,250,0.7307692307692307
1349,35,61.4628,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,348,White,Male,asymptomatic,ZDV only,censoring,110,-170,0.4772727272727273
1350,40,62.1432,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,139,Non-White,Female,asymptomatic,others,censoring,90,-80,0.2631578947368421
1351,35,79.6068,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,505,White,Male,asymptomatic,others,censoring,-50,-400,0.5053763440860215
1352,33,68.04,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,100,-170,0.5245901639344263
1353,37,90.2664,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,641,White,Male,asymptomatic,others,censoring,0,230,0.2916666666666667
1354,28,67.1328,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,141,White,Male,asymptomatic,others,censoring,150,10,0.5641025641025641
1355,37,76.2048,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,768,White,Male,asymptomatic,others,censoring,10,230,0.5352112676056338
1356,28,87.0912,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,97,Non-White,Female,asymptomatic,others,censoring,70,-430,0.1984126984126984
1357,27,67.1328,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,950,Non-White,Female,asymptomatic,others,censoring,160,60,0.2876712328767123
1358,36,70.7616,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,233,Non-White,Male,asymptomatic,others,censoring,-50,-220,0.2966101694915254
1359,30,52.164,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,7,Non-White,Female,symtomatic,others,censoring,-60,160,0.2755102040816326
1360,27,75.2976,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,336,White,Male,asymptomatic,others,censoring,-130,-500,0.5135135135135135
1361,39,76.2048,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,90,-140,0.42857142857142855
1362,39,96.1632,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,166,Non-White,Male,asymptomatic,ZDV only,failure,-180,-500,0.35384615384615387
1363,51,73.0296,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,540,White,Male,asymptomatic,others,censoring,10,-240,0.25862068965517243
1364,52,65.3184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,646,White,Male,asymptomatic,others,censoring,170,200,0.29285714285714287
1365,41,98.4312,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,2283,White,Male,symtomatic,others,failure,20,370,0.18115942028985507
1366,34,64.8648,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,50,-100,0.5125
1367,32,79.38,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,250,270,0.4482758620689655
1368,28,74.75328,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,180,290,0.5373134328358209
1369,28,68.4,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,symtomatic,others,failure,60,220,0.2191780821917808
1370,45,95.7096,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,155,Non-White,Male,asymptomatic,others,censoring,-140,-360,0.4883720930232558
1371,45,109.3176,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,585,White,Male,symtomatic,others,censoring,120,-100,0.2360248447204969
1372,41,68.9472,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,404,White,Male,asymptomatic,ZDV only,censoring,60,-220,0.1926605504587156
1373,35,89.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,181,White,Male,asymptomatic,others,failure,70,450,0.463768115942029
1374,33,77.112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-40,-730,0.18791946308724833
1375,56,75.0708,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,582,White,Male,asymptomatic,others,failure,160,270,0.3389830508474576
1376,37,93.8952,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1384,White,Male,asymptomatic,ZDV only,failure,-70,-210,0.5402298850574713
1377,42,58.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,2851,White,Male,asymptomatic,others,failure,50,40,0.4745762711864407
1378,42,67.8132,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,65,White,Male,asymptomatic,others,censoring,0,-570,0.17204301075268819
1379,31,82.23768,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,359,Non-White,Male,asymptomatic,others,censoring,-10,200,0.8032786885245902
1380,30,73.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,160,180,0.48214285714285715
1381,34,67.5864,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,245,White,Male,asymptomatic,ZDV only,censoring,-50,-170,0.5490196078431373
1382,27,78.4728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,40,210,0.3925233644859813
1383,52,51.4,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,665,Non-White,Male,asymptomatic,others,failure,100,-140,0.47058823529411764
1384,24,56.4732,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,206,Non-White,Male,asymptomatic,others,failure,-110,-260,0.17532467532467533
1385,42,97.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,358,White,Male,asymptomatic,others,censoring,-60,10,0.4939759036144578
1386,43,74.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,816,White,Male,asymptomatic,ZDV only,failure,80,-390,0.30927835051546393
1387,31,114.534,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,685,Non-White,Male,asymptomatic,ZDV only,censoring,60,350,0.25806451612903225
1388,20,63.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,85,White,Male,symtomatic,others,censoring,130,60,0.46808510638297873
1389,43,77.112,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,80,-170,0.15476190476190477
1390,48,69.6276,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,170,490,0.2857142857142857
1391,49,95.7096,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,183,Non-White,Male,asymptomatic,others,censoring,270,210,0.6857142857142857
1392,29,58.0608,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,314,Non-White,Male,asymptomatic,others,censoring,130,70,0.2926829268292683
1393,28,66.6792,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,971,Non-White,Female,asymptomatic,others,failure,-120,-280,0.43478260869565216
1394,29,74.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,160,-240,0.5555555555555556
1395,28,79.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,237,White,Male,asymptomatic,others,failure,-130,-210,0.44
1396,27,97.524,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,495,White,Male,asymptomatic,ZDV only,censoring,160,190,0.43157894736842106
1397,22,81.1944,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,394,Non-White,Female,asymptomatic,others,failure,-240,-380,0.44954128440366975
1398,34,85.5036,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-30,-40,0.4
1399,47,87.9984,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,322,White,Male,asymptomatic,others,failure,30,-300,0.23703703703703705
1400,31,64.8648,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-20,-70,0.5974025974025974
1401,38,91.1736,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,735,White,Male,asymptomatic,others,censoring,60,-50,0.48
1402,32,115.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,456,White,Male,asymptomatic,ZDV only,censoring,-40,-490,0.2916666666666667
1403,21,70.308,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,83,White,Male,asymptomatic,others,censoring,0,180,0.509090909090909
1404,34,105.0084,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,100,-310,0.1564625850340136
1405,31,72.8028,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,718,White,Male,asymptomatic,others,censoring,50,-40,0.484375
1406,32,67.1328,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,0,-110,0.484375
1407,38,65.3184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,300,-50,0.5686274509803921
1408,25,75.2976,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,80,-370,0.45977011494252873
1409,34,81.648,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,50,-400,0.47191011235955055
1410,44,89.8128,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,100,-40,0.30337078651685395
1411,28,73.9368,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,200,470,1.4864864864864864
1412,27,93.8952,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,50,-80,0.30434782608695654
1413,21,58.968,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,220,170,0.5263157894736842
1414,32,91.1736,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-50,100,0.8837209302325582
1415,53,71.442,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-30,280,0.7608695652173914
1416,26,83.4624,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1177,Non-White,Male,asymptomatic,others,failure,-140,150,0.5230769230769231
1417,32,71.2152,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,196,White,Male,asymptomatic,others,failure,76,564,1.6293103448275863
1418,33,66.906,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,780,White,Male,asymptomatic,others,censoring,180,393,0.4629080118694362
1419,35,64.4112,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,91,White,Male,asymptomatic,ZDV only,censoring,-151,-226,0.5273542600896861
1420,38,79.38,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,928,White,Male,symtomatic,others,censoring,-99,-637,0.20254237288135593
1421,26,79.6068,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,548,White,Male,asymptomatic,others,censoring,-109,-112,0.5925925925925926
1422,45,73.9368,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,480,White,Male,symtomatic,others,failure,13,-480,0.11682808716707022
1423,32,79.8336,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1073,White,Male,symtomatic,others,censoring,-86,-224,0.1900383141762452
1424,37,65.772,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,113,White,Male,symtomatic,ZDV only,censoring,33,-286,0.3396584440227704
1425,34,74.3904,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,80,-589,0.11702127659574468
1426,31,72.1224,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,956,White,Male,asymptomatic,others,censoring,52,-337,0.20920840064620355
1427,43,95.256,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,-48,144,0.453125
1428,27,73.2564,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,138,-77,0.3830888697152718
1429,34,65.3184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-10,112,0.36209813874788493
1430,26,73.4832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1053,White,Male,symtomatic,others,failure,63,178,0.41025641025641024
1431,25,48.3084,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,431,White,Male,asymptomatic,others,censoring,-39,-54,0.6257142857142857
1432,40,71.6688,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,128,173,1.0244648318042813
1433,42,62.37,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,249,Non-White,Male,asymptomatic,others,censoring,-187,-420,0.6268844221105527
1434,31,70.308,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,121,White,Male,asymptomatic,others,failure,78,-233,0.32755298651252407
1435,37,65.3184,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,failure,-61,-185,0.1806615776081425
1436,36,72.1224,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,175,Non-White,Male,asymptomatic,others,censoring,-284,106,0.3333333333333333
1437,21,99.792,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,17,Non-White,Female,symtomatic,ZDV only,censoring,73,317,0.2814159292035398
1438,28,65.3184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,46,-474,0.0854563044179297
1439,48,83.4624,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,failure,37,69,0.47163695299837927
1440,29,94.8024,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,250,801,0.32093517534537724
1441,45,127.008,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,390,615,0.32701421800947866
1442,29,68.4936,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,147,215,0.7204081632653061
1443,40,68.04,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,89,74,0.8800738007380073
1444,48,83.4,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1409,White,Male,symtomatic,others,censoring,-5,10,0.38689866939611056
1445,43,65.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,974,White,Male,asymptomatic,ZDV only,failure,-133,-499,0.17123037604965316
1446,31,72.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,273,White,Male,asymptomatic,others,censoring,90,298,0.40713224368499257
1447,31,103.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,942,White,Male,asymptomatic,others,censoring,125,-152,0.29264214046822745
1448,36,77.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,934,White,Male,symtomatic,others,censoring,202,-8,0.29422492401215805
1449,32,102.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,478,White,Male,asymptomatic,others,censoring,77,19,0.4138486312399356
1450,38,102.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-110,-200,0.3150537634408602
1451,35,83.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,121,19,0.5
1452,31,76.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,148,White,Male,asymptomatic,others,censoring,-52,151,0.7109826589595376
1453,39,99.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,402,White,Male,symtomatic,others,censoring,-154,-10,0.2983271375464684
1454,31,90.3,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,422,White,Male,asymptomatic,others,failure,49,123,0.39290780141843973
1455,43,101.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,75,White,Male,asymptomatic,others,censoring,127,579,0.2229299363057325
1456,39,62.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,83,32,0.4654696132596685
1457,31,99.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,364,White,Male,asymptomatic,ZDV only,censoring,-11,174,0.38235294117647056
1458,34,57.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,355,White,Male,asymptomatic,others,failure,162,86,0.19323241317898487
1459,33,102.8,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,13,42,0.710691823899371
1460,27,67.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,262,White,Male,asymptomatic,ZDV only,censoring,-36,-299,0.23847695390781562
1461,29,79.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,606,White,Male,asymptomatic,others,censoring,380,861,0.2625
1462,30,80.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,148,241,0.5346153846153846
1463,28,74.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,184,White,Male,asymptomatic,others,censoring,-88,-376,0.2659279778393352
1464,32,69.8,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,24,-31,0.4909706546275395
1465,45,91.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-59,-137,0.467438494934877
1466,24,67.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,118,White,Female,asymptomatic,others,censoring,127,-158,0.3003875968992248
1467,23,87.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,136,White,Male,symtomatic,others,censoring,162,356,0.5318230852211435
1468,29,65.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,failure,-215,-383,0.3695067264573991
1469,24,65.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,108,Non-White,Male,asymptomatic,ZDV only,censoring,24,52,0.47755834829443444
1470,34,65.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-36,-37,0.21734357848518113
1471,24,71.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,30,Non-White,Male,asymptomatic,others,censoring,-66,-46,0.35064935064935066
1472,31,82.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-4,81,0.18200408997955012
1473,36,62.2,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,514,White,Female,asymptomatic,others,censoring,15,-23,0.592814371257485
1474,29,83.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-10,-215,0.3271889400921659
1475,35,82.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,296,85,0.768352365415987
1476,36,75.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-155,-82,0.4900990099009901
1477,31,74.7,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,165,116,0.5438066465256798
1478,36,88.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,53,84,0.6921641791044776
1479,23,70.308,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,22,-775,0.28125
1480,26,63.7,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-61,-403,0.22980132450331126
1481,29,70.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-342,-1556,0.32867883995703545
1482,20,57.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,71,154,0.6115288220551378
1483,32,86.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,237,277,0.4221105527638191
1484,35,61.2,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-3,89,0.34328358208955223
1485,38,66.3,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,448,279,0.594059405940594
1486,37,60.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,81,12,0.43140243902439024
1487,35,71.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-2,-56,0.3572744014732965
1488,25,79.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,88,106,0.48109965635738833
1489,41,75.7512,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1599,White,Male,asymptomatic,others,censoring,222,364,0.5944540727902946
1490,33,78.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,703,White,Male,asymptomatic,ZDV only,failure,-265,-184,0.6609989373007439
1491,29,78.0192,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,906,Non-White,Male,asymptomatic,ZDV only,censoring,-21,71,0.5573770491803278
1492,36,77.112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,925,White,Male,asymptomatic,ZDV only,censoring,-64,-139,0.5006711409395973
1493,36,86.184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,925,White,Male,asymptomatic,others,censoring,-189,222,0.22535211267605634
1494,40,84.8232,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1282,White,Male,asymptomatic,others,failure,64,233,0.44642857142857145
1495,39,69.6276,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,917,White,Male,symtomatic,others,failure,5,126,0.21688741721854304
1496,30,65.772,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,894,White,Male,asymptomatic,ZDV only,failure,-37,-172,0.3333333333333333
1497,40,82.5552,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,926,White,Male,symtomatic,ZDV only,failure,-392,-47,0.3438395415472779
1498,41,62.1432,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,917,White,Male,asymptomatic,ZDV only,censoring,-135,-38,0.37470542026708564
1499,35,78.4728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,967,White,Male,asymptomatic,others,censoring,-100,-418,0.18584521384928718
1500,42,76.2048,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,938,White,Male,asymptomatic,others,failure,-164,-315,0.6301020408163265
1501,26,80.7408,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-47,15,0.3928980526918671
1502,30,84.3696,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,158,724,0.23851590106007067
1503,38,70.7616,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-81,-205,0.2768627450980392
1504,39,75.2976,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,78,361,0.4353059177532598
1505,27,101.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,190,White,Female,asymptomatic,others,censoring,41,-59,0.48005698005698005
1506,39,63.504,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,54,Non-White,Female,asymptomatic,others,censoring,97,104,0.617737003058104
1507,35,64.8648,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,234,Non-White,Female,asymptomatic,others,censoring,-56,-365,0.5651041666666666
1508,39,82.5552,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,127,544,0.5958188153310104
1509,29,65.772,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,817,White,Male,asymptomatic,others,censoring,-137,-407,0.4718969555035129
1510,33,84.3696,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,888,White,Male,asymptomatic,ZDV only,censoring,-15,126,0.178979436405179
1511,29,70.7616,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,966,White,Male,asymptomatic,others,failure,-170,-720,0.2292857142857143
1512,26,73.9368,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,772,White,Male,asymptomatic,others,censoring,-146,-303,0.20839260312944524
1513,47,85.2768,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,840,White,Male,symtomatic,others,censoring,5,-39,0.4034090909090909
1514,43,88.452,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,843,White,Male,symtomatic,ZDV only,censoring,13,-79,0.34668721109399075
1515,25,61.236,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,symtomatic,others,censoring,33,159,0.6455479452054794
1516,33,78.9264,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,203,50,0.3778040141676505
1517,27,84.3696,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,134,-97,0.31223267750213857
1518,37,79.38,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-108,-106,0.4700854700854701
1519,25,75.5244,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,187,70,0.8336221837088388
1520,28,71.6688,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,111,159,1.1666666666666667
1521,28,76.8852,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-71,127,1.2138228941684666
1522,36,113.4,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,249,White,Female,asymptomatic,others,censoring,281,433,0.566
1523,37,57.0,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,227,White,Female,asymptomatic,others,censoring,57,160,0.8498168498168498
1524,25,67.5864,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-43,-923,0.2582106455266138
1525,36,114.3072,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,197,246,0.39664804469273746
1526,30,69.4008,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-148,-516,0.4734195402298851
1527,39,54.8856,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-69,-336,0.09993734335839599
1528,34,63.504,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,918,Non-White,Male,asymptomatic,others,censoring,-12,354,0.22755417956656346
1529,45,78.246,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,233,White,Male,asymptomatic,ZDV only,failure,-131,-731,0.10129431626336523
1530,41,85.05,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,54,173,0.3829787234042553
1531,22,62.5968,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,31,255,0.45414364640883975
1532,40,97.88688,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,843,Non-White,Female,asymptomatic,others,failure,43,-149,0.5862068965517241
1533,47,104.1012,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-22,-257,0.1248852157943067
1534,32,70.7616,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,576,White,Male,asymptomatic,ZDV only,censoring,33,173,0.4787985865724382
1535,31,83.0088,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-82,-49,0.4910394265232975
1536,31,80.2872,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,19,-103,0.6414201183431952
1537,57,71.2152,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,326,Non-White,Male,asymptomatic,others,failure,-69,-244,0.43686502177068215
1538,35,49.4424,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-123,-193,0.3170381020848311
1539,48,70.308,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,912,White,Male,asymptomatic,others,censoring,-93,-463,0.27010804321728693
1540,34,67.5864,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,171,229,0.4
1541,36,78.38208,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,206,Non-White,Male,asymptomatic,others,censoring,93,17,0.4213917525773196
1542,39,76.6584,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,811,White,Male,asymptomatic,others,censoring,-113,-342,0.43650126156433977
1543,38,76.2048,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,15,White,Male,asymptomatic,others,censoring,44,454,0.40046296296296297
1544,49,76.2048,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,23,-642,0.3869047619047619
1545,35,75.5244,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,909,White,Male,asymptomatic,ZDV only,failure,93,157,0.4
1546,36,67.5864,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1132,White,Male,asymptomatic,others,censoring,88,126,0.5512965050732808
1547,37,82.1016,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,13,-193,0.28113879003558717
1548,42,72.1224,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,606,White,Male,asymptomatic,others,censoring,22,-77,0.46645367412140576
1549,34,70.308,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,960,White,Male,asymptomatic,others,censoring,341,369,0.42003853564547206
1550,35,73.9368,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,59,White,Male,asymptomatic,others,censoring,-14,-297,0.3894500561167228
1551,37,70.308,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,122,120,0.6806883365200764
1552,40,81.8748,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,26,White,Male,symtomatic,ZDV only,censoring,-74,-298,0.14453125
1553,25,77.112,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,676,White,Male,asymptomatic,others,censoring,67,-72,0.4005722460658083
1554,34,86.6376,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,27,Non-White,Male,asymptomatic,others,censoring,19,218,0.31548974943052394
1555,31,64.4112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,17,White,Male,asymptomatic,ZDV only,censoring,0,-37,0.44410876132930516
1556,36,72.3492,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,238,White,Male,asymptomatic,others,censoring,93,289,0.25413966882649386
1557,25,51.4836,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,23,Non-White,Male,asymptomatic,others,censoring,-15,-40,0.4912891986062718
1558,33,74.98008,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,342,White,Male,symtomatic,ZDV only,censoring,-27,-354,0.21630901287553647
1559,30,55.7928,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,95,391,0.21060171919770773
1560,32,72.576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,-39,49,0.1937984496124031
1561,39,80.2872,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,21,-228,0.09338624338624339
1562,32,41.2776,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,6,White,Female,asymptomatic,others,censoring,-51,3,0.6804979253112033
1563,40,75.978,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,291,Non-White,Female,asymptomatic,others,censoring,4,50,0.28780068728522334
1564,40,76.0,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,139,Non-White,Female,asymptomatic,others,censoring,-153,31,0.3201530612244898
1565,23,52.164,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,145,Non-White,Female,asymptomatic,others,censoring,-65,-207,0.48231511254019294
1566,27,83.0088,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-2,106,0.4049429657794677
1567,30,77.3388,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,66,65,0.46238938053097345
1568,31,49.4424,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,57,-110,0.44
1569,28,125.6472,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,138,323,0.45087719298245615
1570,29,58.968,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,175,Non-White,Female,asymptomatic,others,censoring,-86,-10,0.9429735234215886
1571,37,76.2048,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-14,576,0.32444124008651765
1572,50,70.67088,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,148,-63,0.5678391959798995
1573,44,87.5448,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-26,-184,0.4124087591240876
1574,44,89.3592,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,6,-133,0.6363636363636364
1575,37,82.1016,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-18,184,0.41764080765143463
1576,29,100.0188,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-110,24,0.5
1577,37,76.4316,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-120,-850,0.28116983068240126
1578,57,81.1944,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1345,White,Male,symtomatic,ZDV only,failure,-108,-455,0.11254980079681275
1579,45,51.7104,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1466,White,Female,asymptomatic,others,failure,-110,-122,0.3449101796407186
1580,54,86.6376,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1377,White,Male,asymptomatic,others,censoring,43,138,0.452755905511811
1581,43,86.184,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,953,White,Male,asymptomatic,others,censoring,115,-60,0.29257314328582146
1582,44,91.6272,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1157,White,Male,asymptomatic,others,censoring,-7,-247,0.298582995951417
1583,50,83.4624,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1188,White,Male,asymptomatic,others,censoring,-58,-92,0.5292576419213973
1584,30,58.5144,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,112,White,Male,asymptomatic,others,censoring,-136,-351,0.4993548387096774
1585,36,69.4008,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1155,White,Male,asymptomatic,others,censoring,162,1578,0.16387665198237886
1586,30,81.648,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,389,White,Male,asymptomatic,ZDV only,failure,70,-6,0.6007194244604317
1587,39,78.0192,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1151,White,Male,asymptomatic,others,failure,151,204,0.2452431289640592
1588,28,83.2356,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1104,White,Male,asymptomatic,others,failure,-108,324,0.28172817281728174
1589,46,65.5452,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,523,White,Male,asymptomatic,ZDV only,censoring,-6,-9,0.7449324324324325
1590,38,78.0192,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1099,White,Male,asymptomatic,others,failure,-195,-608,0.25015033072760073
1591,29,89.3592,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,406,White,Male,asymptomatic,others,censoring,-224,-31,0.5362485615650172
1592,37,76.6584,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1049,White,Male,asymptomatic,others,censoring,-169,-728,0.29825783972125436
1593,28,85.7304,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-6,-62,0.52
1594,34,62.8236,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,158,161,0.265792610250298
1595,26,79.8336,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,98,-55,0.375
1596,52,61.4628,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,807,Non-White,Female,asymptomatic,others,censoring,250,110,0.6821705426356589
1597,25,70.21728,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,739,Non-White,Male,asymptomatic,others,censoring,-9,-594,0.18582489577129244
1598,32,58.0608,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,356,Non-White,Female,asymptomatic,others,censoring,-120,-179,0.3603431839847474
1599,30,64.638,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,13,White,Female,asymptomatic,others,censoring,-181,-455,0.49037372593431483
1600,49,59.4216,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1084,Non-White,Female,asymptomatic,ZDV only,censoring,-130,-647,0.20696142991533395
1601,35,92.5344,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-26,274,0.3104982206405694
1602,36,57.6072,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,927,Non-White,Female,asymptomatic,others,failure,67,31,0.27534562211981567
1603,32,50.8032,no hemophilia,no homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,191,-127,0.27116827438370844
1604,40,79.38,no hemophilia,no homosexual,IV drugs use,70%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1561,Non-White,Female,asymptomatic,others,failure,67,-37,0.21428571428571427
1605,44,90.4932,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1248,Non-White,Female,asymptomatic,others,failure,-41,-560,0.09338812103100486
1606,27,66.4524,no hemophilia,no homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,943,White,Female,asymptomatic,others,censoring,135,-346,0.29234234234234235
1607,32,64.8648,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,95,Non-White,Female,asymptomatic,others,censoring,-51,-1026,0.14815782597334726
1608,26,47.628,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,202,Non-White,Female,asymptomatic,others,censoring,177,122,0.5741556534508077
1609,40,84.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1484,White,Male,asymptomatic,others,censoring,80,-79,0.3682896379525593
1610,30,65.0,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,416,White,Male,symtomatic,ZDV only,censoring,20,-49,0.3584905660377358
1611,50,72.576,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,885,White,Male,symtomatic,ZDV only,failure,68,-232,0.1794871794871795
1612,33,78.4,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,941,White,Male,asymptomatic,others,censoring,-130,-157,0.3990719257540603
1613,32,64.8648,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,878,White,Female,asymptomatic,others,censoring,-21,473,0.410201912858661
1614,38,75.2,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,940,Non-White,Male,asymptomatic,others,censoring,-27,23,0.19644180874722017
1615,40,110.4516,no hemophilia,no homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,179,White,Male,asymptomatic,others,censoring,0,-172,0.4905998209489705
1616,38,66.2256,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1017,White,Male,asymptomatic,others,censoring,-76,11,0.2877247849882721
1617,47,67.1328,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,22,White,Male,asymptomatic,ZDV only,censoring,-22,-12,0.4725378787878788
1618,37,81.1944,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-73,-319,0.47778981581798485
1619,43,97.524,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,281,84,0.5853658536585366
1620,29,63.9576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,110,-188,0.6075
1621,29,77.112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,155,Non-White,Male,asymptomatic,others,censoring,43,210,0.3685393258426966
1622,31,122.472,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,68,White,Female,symtomatic,others,censoring,1,-253,0.25380710659898476
1623,39,98.4312,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-51,-259,0.2659313725490196
1624,27,83.4624,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,53,Non-White,Female,asymptomatic,others,censoring,33,360,0.8372549019607843
1625,31,63.0504,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,83,White,Female,asymptomatic,others,censoring,320,432,0.7767695099818511
1626,19,59.8752,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,158,Non-White,Female,asymptomatic,others,censoring,19,131,0.5180878552971576
1627,37,63.504,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1191,Non-White,Female,asymptomatic,others,failure,-17,34,0.7047101449275363
1628,58,78.246,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,682,White,Male,asymptomatic,others,failure,181,-10,0.7865384615384615
1629,40,67.1328,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,424,White,Male,asymptomatic,others,failure,-117,-267,0.22951709169831797
1630,31,61.6896,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,751,White,Male,asymptomatic,others,censoring,32,165,0.5285714285714286
1631,40,69.6276,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,-310,-547,0.4258741258741259
1632,24,66.2256,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,493,White,Female,symtomatic,ZDV only,failure,-150,-85,0.5090497737556561
1633,44,91.6272,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1609,White,Female,asymptomatic,others,censoring,-107,-388,0.40942028985507245
1634,31,62.37,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-33,-239,0.375
1635,35,68.2668,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,115,89,0.5960912052117264
1636,33,56.9268,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,104,61,0.7852028639618138
1637,26,56.2464,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,-15,-372,0.36498761354252685
1638,36,117.0288,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,7,-44,0.16205211726384364
1639,33,71.2152,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,39,268,0.3695652173913043
1640,30,61.0092,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,71,-84,0.48291571753986334
1641,59,53.3,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1143,White,Female,asymptomatic,others,failure,49,-10,0.6666666666666666
1642,24,64.04832,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,406,White,Male,asymptomatic,others,censoring,-124,220,0.6666666666666666
1643,41,89.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,980,White,Male,asymptomatic,ZDV only,failure,-2,404,0.3168724279835391
1644,33,72.8028,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,176,White,Male,asymptomatic,others,censoring,86,-32,1.2119565217391304
1645,36,93.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,551,White,Male,asymptomatic,ZDV only,censoring,-75,134,0.3772663877266388
1646,24,62.1432,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,378,-77,0.2755578619615983
1647,29,72.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,160,White,Male,asymptomatic,ZDV only,failure,28,232,0.5752895752895753
1648,29,70.9884,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,139,White,Male,asymptomatic,others,failure,-150,5,0.4665127020785219
1649,35,67.94928,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,105,Non-White,Female,asymptomatic,others,censoring,-18,285,0.440084835630965
1650,25,79.7,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,161,Non-White,Female,asymptomatic,others,failure,-136,-7,0.6169950738916257
1651,35,68.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,205,White,Male,asymptomatic,others,censoring,-15,-5,0.375
1652,32,58.0,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,199,Non-White,Male,asymptomatic,others,censoring,53,17,0.23409893992932862
1653,31,95.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,199,White,Male,asymptomatic,others,censoring,252,117,0.6317991631799164
1654,21,77.9,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-98,114,0.6794171220400729
1655,41,73.0296,hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-77,164,0.6857142857142857
1656,30,68.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,981,White,Male,symtomatic,others,failure,62,271,0.3268206039076377
1657,24,72.5,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,symtomatic,others,censoring,-4,133,0.29734361610968296
1658,18,57.28968,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,344,White,Female,asymptomatic,ZDV only,censoring,-74,-75,0.5809399477806788
1659,47,59.0,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,74,-105,0.4025974025974026
1660,38,79.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,43,-429,0.2575640031031808
1661,40,65.5,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,144,1,0.20266272189349113
1662,23,74.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,failure,-16,-88,0.3023255813953488
1663,37,71.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,170,-218,0.5007407407407407
1664,33,72.576,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,109,-643,0.23540258143822987
1665,27,70.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-19,-179,0.21455576559546313
1666,27,70.7616,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,972,White,Male,asymptomatic,others,failure,205,744,0.337995337995338
1667,41,65.0916,hemophilia,no homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,962,White,Male,asymptomatic,others,censoring,-19,68,0.9428571428571428
1668,33,75.2976,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,965,White,Male,asymptomatic,others,censoring,-216,11,0.3277511961722488
1669,39,80.7408,hemophilia,no homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,806,White,Male,asymptomatic,others,failure,-227,-212,0.3499234303215927
1670,38,82.3,hemophilia,no homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,371,White,Male,asymptomatic,others,censoring,-77,-158,0.4601889338731444
1671,33,65.4,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,369,Non-White,Male,asymptomatic,others,failure,-27,72,0.24206069160197602
1672,24,59.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,195,White,Male,asymptomatic,others,failure,-15,-43,0.20306965761511217
1673,40,71.3,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,-71,-63,0.6311166875784191
1674,30,63.9576,hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1755,White,Male,asymptomatic,others,censoring,97,-50,0.20032051282051283
1675,45,72.7,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,661,White,Male,asymptomatic,others,censoring,-56,220,0.26865671641791045
1676,14,65.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,490,White,Male,asymptomatic,others,censoring,77,-31,0.5289957567185289
1677,37,79.38,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,failure,-184,-849,0.22592067988668554
1678,31,72.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,380,White,Male,asymptomatic,others,censoring,-10,-320,0.48
1679,34,84.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,979,White,Male,asymptomatic,ZDV only,censoring,10,-20,0.3548387096774194
1680,28,64.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-120,-240,0.449438202247191
1681,26,59.8752,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,118,28,0.4885057471264368
1682,32,102.3,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,-102,-610,0.2537313432835821
1683,22,53.298,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,failure,-68,-308,0.2698412698412698
1684,31,64.1844,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,588,Non-White,Male,asymptomatic,others,censoring,57,-861,0.10144927536231885
1685,18,86.4,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,64,64,0.36363636363636365
1686,42,82.3,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,6,Non-White,Female,asymptomatic,ZDV only,censoring,115,75,0.7948717948717948
1687,39,94.3,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,50,-276,0.46
1688,22,60.3288,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,15,-300,0.375
1689,28,66.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-45,-246,0.8888888888888888
1690,47,74.844,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,-294,-196,0.42857142857142855
1691,25,66.2256,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,62,White,Male,asymptomatic,ZDV only,censoring,-209,-119,1.1724137931034482
1692,36,51.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-72,14,0.24193548387096775
1693,25,84.18816,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1286,White,Male,asymptomatic,ZDV only,failure,-84,-135,0.5490196078431373
1694,37,81.10368,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,898,White,Male,asymptomatic,others,failure,-100,-151,0.5434782608695652
1695,25,63.59472,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1856,White,Male,asymptomatic,others,failure,-126,228,0.23728813559322035
1696,28,68.4936,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1756,White,Male,asymptomatic,others,censoring,-184,-31,0.8837209302325582
1697,27,94.89312,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,188,White,Male,asymptomatic,others,failure,80,58,0.43023255813953487
1698,37,83.28096,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,45,-25,0.6
1699,38,67.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,70,-180,0.29310344827586204
1700,25,68.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,10,White,Male,symtomatic,others,failure,-150,-356,0.37117903930131
1701,40,71.6,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,238,White,Male,asymptomatic,others,censoring,-40,30,0.9428571428571428
1702,34,74.0,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,90,340,0.14285714285714285
1703,24,65.2,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,symtomatic,others,failure,-60,-590,0.10144927536231885
1704,40,91.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,961,White,Male,asymptomatic,others,censoring,70,110,0.2777777777777778
1705,37,66.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,854,White,Male,asymptomatic,others,censoring,100,160,0.5185185185185185
1706,42,93.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-30,-190,0.16556291390728478
1707,28,159.93936,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-427,-1573,0.20967741935483872
1708,49,56.42784,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-86,-466,0.390625
1709,34,86.00256,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,24,-60,0.7073170731707317
1710,31,85.14072,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,failure,-1,140,0.925
1711,29,65.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,90,White,Male,asymptomatic,others,censoring,-60,-390,0.4818181818181818
1712,24,81.1,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,7,Non-White,Female,asymptomatic,others,censoring,-120,-10,0.6774193548387096
1713,31,56.3,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,510,White,Male,asymptomatic,others,failure,-60,-200,0.22807017543859648
1714,61,69.8,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,110,350,0.39285714285714285
1715,33,101.0,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,106,White,Male,asymptomatic,others,failure,-90,-140,0.46511627906976744
1716,26,82.2,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,173,White,Female,asymptomatic,ZDV only,censoring,-150,-50,0.5773195876288659
1717,32,83.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,120,156,0.45
1718,30,69.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,152,White,Male,asymptomatic,others,censoring,50,-146,0.1152073732718894
1719,38,69.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,41,Non-White,Male,asymptomatic,others,censoring,-10,-430,0.13609467455621302
1720,46,86.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,384,56,0.8301886792452831
1721,36,91.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,124,-295,0.21455938697318008
1722,32,69.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-40,-90,0.7222222222222222
1723,25,103.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,508,White,Male,symtomatic,ZDV only,failure,20,340,0.32941176470588235
1724,45,75.3,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,391,White,Female,symtomatic,ZDV only,censoring,-20,-108,0.46153846153846156
1725,46,72.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,477,White,Male,symtomatic,ZDV only,censoring,-10,-290,0.1761006289308176
1726,26,67.2,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,540,White,Male,symtomatic,others,censoring,70,-300,0.21568627450980393
1727,34,63.2,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,662,White,Male,asymptomatic,others,censoring,190,80,0.5416666666666666
1728,22,62.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,60,White,Male,asymptomatic,ZDV only,censoring,-20,-10,0.6495098039215687
1729,32,84.8232,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,45,White,Male,symtomatic,others,failure,-37,-147,0.22807017543859648
1730,23,67.8132,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-126,-354,0.31746031746031744
1731,24,68.4936,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,failure,-22,-60,0.6041666666666666
1732,32,76.8852,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,25,-397,0.20588235294117646
1733,33,74.1636,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,147,153,0.6304347826086957
1734,35,96.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,6,White,Male,asymptomatic,others,failure,20,-10,0.325
1735,29,73.9,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,70,-190,0.48598130841121495
1736,30,76.3,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,100,130,0.5151515151515151
1737,38,72.9,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,120,154,0.34050179211469533
1738,23,82.1,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,616,Non-White,Female,asymptomatic,others,censoring,190,70,0.35185185185185186
1739,24,71.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,20,-210,0.5952380952380952
1740,48,85.4,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,10,-155,0.8155339805825242
1741,47,89.1,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,50,150,0.21568627450980393
1742,30,60.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-30,-160,0.609375
1743,26,69.0,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,140,-300,0.5416666666666666
1744,32,97.9,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,failure,70,-130,0.21367521367521367
1745,27,86.6,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,210,395,0.6666666666666666
1746,32,81.5,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-10,-108,0.367816091954023
1747,27,103.4208,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-3,136,0.16666666666666666
1748,30,77.7924,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-76,185,0.6109375
1749,27,66.6,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,-64,-38,0.6808510638297872
1750,25,53.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,160,90,0.4583333333333333
1751,39,113.4,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,-242,96,1.1515151515151516
1752,40,68.7204,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-150,-90,0.7142857142857143
1753,32,64.4112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-11,235,0.6444444444444445
1754,46,84.8232,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,failure,-347,-543,0.52
1755,32,67.1328,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-36,-454,0.07352941176470588
1756,22,57.1536,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-18,-43,0.5283018867924528
1757,36,61.6896,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-146,-636,0.3137254901960784
1758,39,77.5656,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,162,Non-White,Female,asymptomatic,others,censoring,115,293,0.209478672985782
1759,35,112.7196,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,953,White,Male,asymptomatic,others,failure,-40,-260,0.3118279569892473
1760,41,92.3076,no hemophilia,homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,996,White,Male,asymptomatic,others,censoring,-20,-260,0.2222222222222222
1761,36,93.8952,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,862,Non-White,Male,asymptomatic,ZDV only,censoring,-10,-20,0.25961538461538464
1762,37,47.628,no hemophilia,no homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,561,White,Female,asymptomatic,others,censoring,-80,-240,0.3763440860215054
1763,53,107.5032,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,888,White,Male,asymptomatic,others,failure,-90,30,0.27358490566037735
1764,32,65.3184,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,471,White,Male,asymptomatic,others,censoring,-20,-50,0.6101694915254238
1765,45,94.5756,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,372,Non-White,Male,symtomatic,ZDV only,censoring,140,-70,0.20394736842105263
1766,41,86.184,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,371,Non-White,Female,asymptomatic,others,censoring,90,-80,0.25203252032520324
1767,44,55.5,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,181,Non-White,Female,asymptomatic,others,censoring,100,110,0.8541666666666666
1768,44,79.38,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,14,White,Male,asymptomatic,ZDV only,censoring,-60,-160,0.14084507042253522
1769,42,62.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,539,Non-White,Female,symtomatic,ZDV only,failure,-150,-380,0.425531914893617
1770,30,78.83568,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,312,White,Male,asymptomatic,others,censoring,170,190,0.47191011235955055
1771,40,80.5,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,751,White,Male,asymptomatic,others,censoring,-40,-1128,0.1819560272934041
1772,36,83.4624,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,655,White,Male,asymptomatic,ZDV only,failure,-40,170,0.4444444444444444
1773,30,135.1728,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,30,White,Male,symtomatic,others,censoring,0,130,0.19642857142857142
1774,33,83.0088,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,785,White,Male,asymptomatic,others,failure,140,-40,0.44
1775,39,75.0708,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,449,Non-White,Male,asymptomatic,others,failure,-70,-180,0.32608695652173914
1776,31,85.7304,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,504,White,Male,asymptomatic,ZDV only,censoring,60,210,0.8536585365853658
1777,40,70.0812,no hemophilia,no homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,150,-230,0.32
1778,42,76.2048,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,275,Non-White,Male,symtomatic,others,failure,-60,-220,0.2
1779,33,70.5348,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,762,White,Female,asymptomatic,others,censoring,60,-10,0.41904761904761906
1780,29,92.5344,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,524,White,Male,symtomatic,others,censoring,-40,-420,0.23529411764705882
1781,40,93.6684,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,792,Non-White,Male,asymptomatic,others,censoring,510,190,0.31125827814569534
1782,41,87.0912,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,310,White,Male,symtomatic,others,censoring,60,30,0.5357142857142857
1783,45,68.2668,no hemophilia,no homosexual,IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,653,Non-White,Male,asymptomatic,others,censoring,-20,-220,0.41836734693877553
1784,41,73.2564,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,777,White,Male,asymptomatic,others,failure,-70,150,0.30434782608695654
1785,29,94.8024,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,70,-170,0.2857142857142857
1786,37,88.9056,no hemophilia,homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,629,White,Male,asymptomatic,others,failure,-60,-170,0.11711711711711711
1787,45,60.7824,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,743,White,Female,asymptomatic,ZDV only,failure,-160,-370,0.3522727272727273
1788,34,72.576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,150,130,0.4262295081967213
1789,31,56.7,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,822,White,Male,asymptomatic,others,censoring,0,70,0.3114754098360656
1790,27,64.77408,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,110,300,0.5795454545454546
1791,30,52.6176,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,2,White,Male,symtomatic,ZDV only,censoring,80,-620,0.13008130081300814
1792,31,63.504,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-30,70,0.23958333333333334
1793,37,87.0912,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,6,White,Male,asymptomatic,others,censoring,10,-280,0.4639175257731959
1794,26,105.9156,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-60,-1460,0.08463949843260188
1795,40,76.2048,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,803,Non-White,Female,asymptomatic,others,censoring,40,-50,0.4297520661157025
1796,33,68.4936,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,70,60,0.2289156626506024
1797,45,76.8852,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,99,136,0.375
1798,32,96.1632,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,0,-20,0.627906976744186
1799,27,65.3184,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,50,160,0.7105263157894737
1800,37,66.6792,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,190,370,1.1777777777777778
1801,37,73.0296,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1737,White,Male,asymptomatic,others,censoring,42,124,0.2982062780269058
1802,43,69.8544,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1267,White,Male,asymptomatic,others,censoring,-53,83,0.7552447552447552
1803,28,58.5144,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1016,Non-White,Male,asymptomatic,others,censoring,-74,-284,0.6274285714285714
1804,41,70.308,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,621,White,Male,asymptomatic,others,censoring,202,337,0.5886850152905199
1805,39,74.6172,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1635,White,Male,asymptomatic,others,censoring,-40,23,0.5440414507772021
1806,38,83.916,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1089,White,Male,asymptomatic,others,censoring,-117,-334,0.3118556701030928
1807,53,69.8544,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1108,White,Male,asymptomatic,others,censoring,19,788,0.5332050048123196
1808,33,73.6,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1080,White,Male,asymptomatic,others,failure,79,242,0.571041948579161
1809,36,86.184,no hemophilia,homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,575,White,Male,asymptomatic,others,censoring,-59,-136,0.5453074433656958
1810,32,86.6376,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,413,White,Male,asymptomatic,others,censoring,-23,-48,0.5678294573643411
1811,41,78.0192,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,472,White,Male,asymptomatic,ZDV only,failure,-103,-283,0.37339055793991416
1812,49,81.648,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,111,White,Male,asymptomatic,others,censoring,78,-95,0.6416309012875536
1813,40,83.916,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,353,White,Male,asymptomatic,ZDV only,failure,-13,118,0.3456221198156682
1814,31,78.9264,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,842,Non-White,Male,asymptomatic,others,censoring,23,-196,0.6306209850107066
1815,39,63.0504,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,19,White,Male,asymptomatic,others,censoring,-2,-198,0.36689814814814814
1816,30,62.5968,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,566,Non-White,Male,symtomatic,others,censoring,11,-12,0.32796780684104626
1817,46,78.0192,no hemophilia,homosexual,IV drugs use,80%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,76,Non-White,Male,asymptomatic,others,censoring,130,302,0.31297709923664124
1818,35,72.576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,28,White,Male,symtomatic,others,censoring,130,470,0.36006825938566556
1819,28,77.112,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,135,-74,0.5752608047690015
1820,44,66.6792,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,447,Non-White,Male,asymptomatic,others,censoring,77,284,0.3756906077348066
1821,26,75.7512,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,409,Non-White,Female,asymptomatic,others,censoring,117,69,0.33856502242152464
1822,37,58.968,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,76,-235,0.5341409691629956
1823,30,48.0816,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,12,156,0.3387241689128482
1824,29,72.2,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,517,Non-White,Female,symtomatic,ZDV only,failure,-65,-50,0.23836276083467095
1825,37,105.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,41,309,0.15512820512820513
1826,25,56.2464,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,199,51,0.8803245436105477
1827,19,74.844,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-51,51,1.1724941724941724
1828,27,60.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-182,-325,0.4363791631084543
1829,27,53.9784,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,816,Non-White,Female,asymptomatic,others,censoring,75,-200,0.21160714285714285
1830,48,73.2564,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-181,-135,0.9161904761904762
1831,41,104.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1320,White,Male,asymptomatic,others,censoring,-28,88,0.8698517298187809
1832,28,88.6,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,84,-32,0.7140939597315437
1833,30,73.8,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,121,59,0.8651685393258427
1834,42,56.2,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-152,128,0.9522184300341296
1835,20,72.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,539,Non-White,Male,asymptomatic,ZDV only,censoring,34,-50,0.489749430523918
1836,29,86.6376,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,939,White,Male,asymptomatic,others,censoring,115,314,0.25
1837,33,120.6576,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-187,317,0.3635593220338983
1838,34,70.308,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,124,Non-White,Male,asymptomatic,ZDV only,failure,137,396,0.31476997578692495
1839,52,61.236,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,933,White,Male,symtomatic,others,censoring,91,-214,0.19987468671679198
1840,32,66.6792,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,267,Non-White,Male,asymptomatic,ZDV only,failure,111,330,0.2622549019607843
1841,30,73.9368,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-1,275,0.2635270541082164
1842,28,98.8848,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,219,Non-White,Male,asymptomatic,others,censoring,45,-581,0.33874538745387456
1843,41,66.2256,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1102,White,Male,asymptomatic,ZDV only,censoring,11,228,0.2837528604118993
1844,19,54.432,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,76,-71,0.6338983050847458
1845,57,50.8032,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-70,184,0.5749279538904899
1846,42,68.04,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,133,-437,0.2802631578947368
1847,28,68.2668,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,-166,90,0.3416038989809482
1848,32,79.6068,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,213,Non-White,Female,asymptomatic,others,censoring,125,22,0.7467532467532467
1849,29,61.4628,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,47,-165,0.38366988586479367
1850,48,72.1224,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,310,699,0.3852080123266564
1851,26,50.3496,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-61,-65,0.3472222222222222
1852,30,92.0808,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-29,-48,0.32479627473806755
1853,33,43.00128,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-1,127,0.49318801089918257
1854,29,63.9576,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,73,-427,0.2365747460087083
1855,40,77.112,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,9,-66,0.21374045801526717
1856,37,81.648,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,134,142,0.6578073089700996
1857,36,82.1016,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-174,-341,0.6608391608391608
1858,32,65.4,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,588,Non-White,Female,asymptomatic,others,failure,-10,30,0.43859649122807015
1859,26,56.8,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,225,Non-White,Female,asymptomatic,others,censoring,-109,-148,0.4714285714285714
1860,32,48.62592,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,694,Non-White,Female,asymptomatic,ZDV only,failure,-70,-430,0.23529411764705882
1861,28,61.6896,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,290,Non-White,Female,asymptomatic,others,failure,60,630,0.4523809523809524
1862,28,50.3496,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,672,Non-White,Female,asymptomatic,others,censoring,-142,-481,0.31093279839518556
1863,34,72.576,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,10,-60,0.2781954887218045
1864,33,68.4936,no hemophilia,no homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,80,-20,0.14912280701754385
1865,27,52.70832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-140,-430,0.23333333333333334
1866,38,59.8752,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-110,-100,0.45185185185185184
1867,39,67.1328,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-60,20,0.6086956521739131
1868,43,79.8336,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,70,200,0.4444444444444444
1869,27,63.86688,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,20,-70,0.494949494949495
1870,39,73.9368,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,170,320,0.5753424657534246
1871,28,52.164,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,30,-70,0.4606741573033708
1872,31,68.9472,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1033,White,Female,symtomatic,others,censoring,230,398,0.35945945945945945
1873,21,58.968,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,349,White,Female,asymptomatic,others,censoring,21,127,0.5704809286898839
1874,34,82.1016,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-16,-338,0.34774193548387095
1875,45,90.2664,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,252,183,0.35573580533024335
1876,27,70.7616,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,69,159,0.4664310954063604
1877,43,83.0088,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,217,48,0.2727272727272727
1878,38,103.194,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,149,441,0.2724795640326976
1879,38,63.7308,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1647,White,Male,asymptomatic,ZDV only,censoring,-187,-288,0.596078431372549
1880,36,70.7616,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,94,White,Male,asymptomatic,others,censoring,69,89,0.3725690890481064
1881,35,76.4316,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1495,Non-White,Male,asymptomatic,ZDV only,censoring,-223,-51,0.7620396600566572
1882,36,75.7512,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,691,White,Male,asymptomatic,others,censoring,406,298,0.3772972972972973
1883,36,67.3596,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,675,White,Male,asymptomatic,others,censoring,170,148,0.8375451263537906
1884,43,94.8024,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,396,White,Male,asymptomatic,others,censoring,-36,-464,0.23875802997858672
1885,29,80.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-37,-152,0.4601226993865031
1886,34,73.4832,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1011,White,Male,asymptomatic,others,failure,67,-338,0.4046242774566474
1887,33,63.504,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,919,White,Female,asymptomatic,ZDV only,censoring,89,-62,0.7891156462585034
1888,39,80.9676,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,327,White,Male,asymptomatic,ZDV only,censoring,-15,-64,0.8091603053435115
1889,28,70.7616,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,600,White,Male,asymptomatic,others,censoring,-62,-442,0.39658119658119656
1890,33,73.0296,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,814,Non-White,Female,symtomatic,others,censoring,-45,155,0.19298245614035087
1891,29,78.6996,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,723,White,Male,asymptomatic,others,censoring,-42,-239,0.20833333333333334
1892,42,70.5348,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1057,White,Male,asymptomatic,others,censoring,-23,-653,0.1938296445338699
1893,30,67.1328,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,327,White,Male,asymptomatic,others,failure,-146,-962,0.16676999380037197
1894,40,69.8544,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,690,White,Male,asymptomatic,others,censoring,64,-385,0.220616570327553
1895,33,74.844,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,595,White,Male,asymptomatic,others,censoring,96,57,0.5557251908396946
1896,51,68.04,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,389,Non-White,Male,asymptomatic,others,censoring,72,-137,0.3818525519848771
1897,44,77.5656,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,448,White,Male,asymptomatic,ZDV only,censoring,119,107,0.3137254901960784
1898,41,83.4624,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1174,White,Female,asymptomatic,others,failure,-50,-219,0.25749167591564925
1899,28,87.9984,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,832,White,Female,asymptomatic,others,failure,20,190,0.4514285714285714
1900,39,73.0296,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-61,128,0.41914191419141916
1901,35,89.3592,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,11,24,0.45588235294117646
1902,63,86.6376,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-153,110,1.1042830540037243
1903,33,66.4524,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,62,232,0.3875
1904,30,70.9884,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,184,-478,0.22953328232593725
1905,47,84.8,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,2,-278,0.6536312849162011
1906,27,70.5348,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,106,308,0.2423076923076923
1907,26,70.0812,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,173,109,0.38857142857142857
1908,27,62.5968,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,-161,-350,0.6548582995951417
1909,45,81.33048,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,629,White,Male,asymptomatic,others,failure,-12,-179,0.14285714285714285
1910,35,70.5,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-57,-734,0.12063632346442775
1911,27,74.844,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,90,White,Male,asymptomatic,others,censoring,-37,-313,0.311660777385159
1912,51,102.3,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,50,-141,0.7264653641207816
1913,25,58.7,no hemophilia,homosexual,no IV drugs use,70%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,19,-184,0.148895292987512
1914,54,75.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,symtomatic,others,failure,-95,-343,0.29312762973352036
1915,28,83.0088,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-53,277,0.2923076923076923
1916,40,70.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,10,24,0.35735735735735735
1917,60,65.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-43,152,0.8049382716049382
1918,32,64.1844,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-107,-181,0.75
1919,41,63.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,580,136,0.21138669673055244
1920,33,75.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,236,250,0.3848797250859107
1921,39,74.43576,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,145,368,0.6506410256410257
1922,31,72.8,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,301,274,0.548951048951049
1923,34,66.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,37,-35,0.31649484536082473
1924,33,74.4,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,157,999,0.36869565217391304
1925,36,77.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,217,867,0.23529411764705882
1926,32,84.1,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-38,-226,0.2725480532281912
1927,28,67.6,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,79,82,0.3888888888888889
1928,32,78.0192,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,5,38,0.3848314606741573
1929,28,88.9,no hemophilia,homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-71,-512,0.30931796349663787
1930,31,71.8,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,24,299,0.3497723823975721
1931,30,36.78696,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-33,-122,0.3333333333333333
1932,47,69.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,492,White,Male,asymptomatic,others,failure,-79,-498,0.24305555555555555
1933,40,85.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,217,Non-White,Male,symtomatic,ZDV only,failure,10,220,0.3412698412698413
1934,28,61.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-60,-10,0.8780487804878049
1935,35,55.5,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,symtomatic,others,censoring,-60,-270,0.379746835443038
1936,27,96.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,250,-30,0.44360902255639095
1937,28,73.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,failure,-41,-1565,0.08954171562867215
1938,39,83.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,90,-140,0.5873015873015873
1939,37,72.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,852,White,Female,asymptomatic,ZDV only,failure,-200,-860,0.13732394366197184
1940,36,69.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,110,170,0.5588235294117647
1941,33,67.4,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-102,-350,0.40576923076923077
1942,30,75.9,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-237,-76,0.6105263157894737
1943,39,112.5,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,383,Non-White,Female,symtomatic,ZDV only,censoring,-40,40,0.6545454545454545
1944,45,78.0,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-54,45,0.7755102040816326
1945,37,87.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,70,360,0.3096774193548387
1946,39,71.3,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-60,10,0.47572815533980584
1947,21,77.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,10,160,0.3228346456692913
1948,36,57.5,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,60,-410,0.11510791366906475
1949,42,49.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,290,-60,0.19402985074626866
1950,35,64.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,240,580,0.25742574257425743
1951,31,45.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,failure,-110,-180,0.4380165289256198
1952,45,84.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-20,-40,0.3783783783783784
1953,31,80.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-10,-220,0.2982456140350877
1954,37,89.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-100,-180,0.3577981651376147
1955,29,54.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1201,White,Female,symtomatic,others,failure,36,158,0.30033003300330036
1956,23,60.5,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,994,Non-White,Female,asymptomatic,others,censoring,23,-51,1.2642276422764227
1957,51,55.3,no hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,129,White,Female,symtomatic,others,censoring,104,456,0.3606770833333333
1958,29,64.2,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,ZDV only,failure,-66,-29,0.19337016574585636
1959,29,67.7,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-282,-531,0.4657142857142857
1960,38,94.5,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,failure,-100,-75,0.5789473684210527
1961,39,63.1,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,failure,-78,-98,0.6785714285714286
1962,51,119.2968,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-37,113,0.4695121951219512
1963,49,55.7,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,607,White,Female,asymptomatic,others,censoring,152,149,0.4
1964,38,84.91392,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-107,-224,0.4716981132075472
1965,31,77.5656,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,0,36,0.5106382978723404
1966,32,64.4112,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,863,White,Female,asymptomatic,ZDV only,failure,-45,69,1.04
1967,39,85.7304,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-302,-20,0.9259259259259259
1968,26,86.184,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,-163,-448,0.3114754098360656
1969,33,65.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-7,100,0.18333333333333332
1970,51,68.4936,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1034,White,Female,asymptomatic,others,censoring,6,-54,0.5892857142857143
1971,41,80.2872,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,failure,-81,-231,0.37735849056603776
1972,41,60.0,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,343,White,Female,asymptomatic,others,censoring,-49,-82,0.5510204081632653
1973,43,62.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,105,-14,1.0
1974,29,88.17984,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,ZDV only,failure,152,-319,0.4375
1975,25,74.9,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,227,134,0.39285714285714285
1976,34,70.1,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,79,213,0.38461538461538464
1977,40,87.0,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,295,199,0.5124378109452736
1978,27,90.08496,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,133,-96,0.44680851063829785
1979,31,81.1944,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,516,White,Female,asymptomatic,others,censoring,267,193,0.5849056603773585
1980,30,71.3,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,153,289,0.6735751295336787
1981,29,67.5864,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,11,-106,0.5652173913043478
1982,47,53.9784,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,ZDV only,censoring,-131,-229,0.7911111111111111
1983,35,85.7304,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-104,-198,0.6823899371069182
1984,27,70.7616,no hemophilia,homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,79,189,0.8281622911694511
1985,31,76.11408,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,48,210,0.5949008498583569
1986,27,72.5,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,90,2,1.5045871559633028
1987,45,71.3,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-77,-159,0.5908289241622575
1988,52,91.1736,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,22,-62,0.3005050505050505
1989,29,68.9,no hemophilia,no homosexual,IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,9,-776,0.19987546699875466
1990,37,86.184,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,-270,-870,0.3146067415730337
1991,32,63.6,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,719,White,Female,asymptomatic,others,censoring,-100,-240,0.5964912280701754
1992,40,78.9264,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,50,90,0.358695652173913
1993,47,62.5968,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,385,White,Female,asymptomatic,others,failure,-30,-90,0.4782608695652174
1994,39,62.5968,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,269,White,Female,asymptomatic,others,censoring,-100,-240,0.6363636363636364
1995,62,98.8848,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-50,-470,0.41346153846153844
1996,34,72.1224,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1035,White,Female,asymptomatic,others,censoring,460,550,0.4861111111111111
1997,40,62.5968,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,514,White,Female,asymptomatic,ZDV only,failure,40,1370,0.23295454545454544
1998,36,83.916,no hemophilia,homosexual,IV drugs use,70%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,symtomatic,others,censoring,10,10,0.5454545454545454
1999,23,93.8952,no hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,others,censoring,110,130,0.547945205479452
2000,44,53.5248,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,101,White,Female,asymptomatic,others,censoring,30,-300,0.30392156862745096
2001,43,59.0,no hemophilia,no homosexual,IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Female,asymptomatic,ZDV only,censoring,130,120,0.3333333333333333
2002,34,96.6168,no hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,50,370,0.358974358974359
2003,44,77.112,no hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,41,26,0.8231132075471698
2004,39,72.3,hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,986,White,Male,asymptomatic,ZDV only,censoring,4,18,0.3802145411203814
2005,21,68.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,others,censoring,9,-95,0.6327769347496206
2006,27,70.2,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,60,84,0.48242811501597443
2007,29,62.5,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,221,White,Male,symtomatic,ZDV only,censoring,-92,-162,0.6255778120184899
2008,32,75.0,hemophilia,no homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,174,White,Male,asymptomatic,others,censoring,-42,-10,1.2576112412177987
2009,38,74.1636,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,448,White,Male,symtomatic,others,failure,-41,-171,0.2792887029288703
2010,16,58.0608,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,333,White,Male,asymptomatic,others,censoring,-44,138,0.40728476821192056
2011,24,80.7408,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,872,Non-White,Female,asymptomatic,others,censoring,-49,9,0.32689987937273823
2012,22,52.75368,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,565,White,Female,asymptomatic,others,censoring,-10,67,0.25355450236966826
2013,44,81.1944,hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,411,White,Male,asymptomatic,others,censoring,-23,-349,0.37091757387247276
2014,13,32.6592,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,553,White,Male,symtomatic,others,censoring,169,559,0.6105990783410138
2015,17,83.916,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,501,White,Male,asymptomatic,others,censoring,-92,-172,0.3394575678040245
2016,24,90.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,881,White,Male,asymptomatic,others,censoring,66,-81,0.35986159169550175
2017,30,57.834,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,865,White,Male,asymptomatic,ZDV only,censoring,-186,-253,0.4492481203007519
2018,35,85.7304,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,136,White,Male,asymptomatic,others,censoring,114,69,0.47
2019,23,63.1,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,344,White,Male,asymptomatic,ZDV only,censoring,-61,-143,0.5722222222222222
2020,20,77.112,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,86,71,0.6004842615012107
2021,33,84.7,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,177,White,Female,asymptomatic,others,censoring,-174,-1012,0.12158808933002481
2022,32,72.2,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,942,White,Male,asymptomatic,ZDV only,censoring,41,130,0.3651399491094148
2023,23,63.9576,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,693,White,Male,asymptomatic,others,censoring,-3,221,0.5170340681362725
2024,25,62.37,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,13,-498,0.306136210384356
2025,33,73.0296,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,133,-448,0.265379113018598
2026,33,72.576,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,112,White,Male,asymptomatic,ZDV only,censoring,2,72,0.5397815912636506
2027,23,80.7408,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,843,White,Male,asymptomatic,others,censoring,-32,122,0.7594202898550725
2028,62,81.648,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-57,-138,0.3121495327102804
2029,19,77.88312,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,788,White,Male,asymptomatic,others,censoring,-78,-708,0.25382755842062854
2030,42,60.01128,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1192,White,Male,asymptomatic,others,censoring,4,-59,0.39263803680981596
2031,30,92.5344,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,235,White,Male,asymptomatic,others,censoring,24,-317,0.28653295128939826
2032,28,108.4104,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-92,-183,0.39941902687000724
2033,19,70.308,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,667,White,Male,asymptomatic,others,censoring,100,-117,0.44906900328587074
2034,28,114.7608,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-78,-189,0.4
2035,54,93.2148,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-60,-28,1.2012012012012012
2036,48,81.1944,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-167,43,2.6045197740112993
2037,44,82.1016,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,918,White,Male,asymptomatic,others,censoring,-174,-113,1.3942558746736293
2038,24,49.896,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,819,Non-White,Male,asymptomatic,others,censoring,70,60,0.2
2039,14,54.2052,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,610,Non-White,Male,asymptomatic,others,censoring,10,-240,0.24166666666666667
2040,16,54.8856,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,833,Non-White,Male,asymptomatic,others,censoring,80,-30,0.49473684210526314
2041,23,66.906,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,70,229,0.3527272727272727
2042,18,56.8,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,805,Non-White,Male,asymptomatic,ZDV only,failure,-126,-474,0.21579358874120408
2043,32,74.3,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,156,White,Male,asymptomatic,others,censoring,102,90,1.0285714285714285
2044,28,72.03168,hemophilia,no homosexual,no IV drugs use,100%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,88,White,Male,asymptomatic,ZDV only,failure,-69,-78,0.6590909090909091
2045,18,75.2976,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-7,-58,0.5776315789473684
2046,30,83.82528,hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,28,-94,0.46096654275092935
2047,37,92.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,94,26,0.214
2048,32,65.95344,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,421,White,Male,asymptomatic,ZDV only,failure,-91,-218,0.5098039215686274
2049,21,62.86896,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,181,White,Male,asymptomatic,others,censoring,-90,-379,0.21998078770413065
2050,24,89.8128,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,failure,-7,-116,0.19975186104218362
2051,12,41.4,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,89,143,0.9585987261146497
2052,13,62.86896,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,366,White,Male,asymptomatic,others,censoring,-159,-132,0.5493827160493827
2053,31,81.8,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-83,-1062,0.30948225712623617
2054,21,80.514,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,160,White,Male,asymptomatic,ZDV only,failure,-27,263,0.684931506849315
2055,25,80.2872,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,852,White,Male,asymptomatic,others,censoring,111,11,0.796875
2056,28,76.8852,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,524,Non-White,Male,asymptomatic,others,censoring,-19,-341,0.2725647899910634
2057,33,115.53192,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,others,censoring,0,-1391,0.17637271214642264
2058,32,70.2,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1417,White,Male,asymptomatic,others,censoring,-6,-990,0.11242816091954023
2059,42,74.844,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1983,White,Male,asymptomatic,others,failure,56,198,0.40875912408759124
2060,52,80.2872,hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,816,White,Male,asymptomatic,others,failure,45,89,0.3274647887323944
2061,44,80.0604,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,723,Non-White,Male,asymptomatic,others,censoring,-86,-471,0.20037105751391465
2062,14,41.0508,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,218,322,0.47733580018501387
2063,20,71.9,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-114,56,0.3448275862068966
2064,35,80.514,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,Non-White,Male,asymptomatic,ZDV only,censoring,-87,-143,0.4257167680278019
2065,21,64.4,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,667,White,Male,asymptomatic,ZDV only,failure,-75,81,0.5188172043010753
2066,38,85.4,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,694,White,Male,asymptomatic,others,censoring,-5,-205,0.5087719298245614
2067,40,86.4108,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,715,White,Male,asymptomatic,others,censoring,72,56,0.7493670886075949
2068,27,60.3288,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,928,White,Male,asymptomatic,ZDV only,censoring,-24,-248,0.14707813525935653
2069,12,53.1,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,902,White,Male,asymptomatic,others,censoring,498,870,0.4606741573033708
2070,27,60.6,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,800,White,Male,asymptomatic,others,censoring,35,-225,0.304635761589404
2071,28,68.2,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,832,White,Male,asymptomatic,ZDV only,failure,-102,-106,0.8580246913580247
2072,12,31.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,2500,White,Male,asymptomatic,others,failure,-71,-52,1.0625
2073,14,64.3,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,387,Non-White,Male,asymptomatic,others,failure,-102,208,0.36720997123681687
2074,30,73.0296,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,264,White,Male,asymptomatic,others,censoring,-122,-93,1.4623217922606924
2075,24,83.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,625,White,Male,asymptomatic,others,censoring,107,142,0.616643929058663
2076,15,46.8,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,481,White,Male,asymptomatic,others,failure,-139,-191,0.4449213161659514
2077,21,75.4,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,192,Non-White,Male,asymptomatic,ZDV only,failure,-42,207,0.18181818181818182
2078,16,41.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,626,White,Male,asymptomatic,others,censoring,-5,-20,0.246104245029554
2079,16,60.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,844,White,Male,symtomatic,others,censoring,-117,-128,0.975609756097561
2080,21,93.6,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,925,Non-White,Male,asymptomatic,ZDV only,censoring,-230,-261,0.5381319622964867
2081,35,73.2,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,916,White,Male,asymptomatic,others,censoring,-212,-294,0.5108267716535433
2082,24,66.4,hemophilia,no homosexual,IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,735,White,Male,asymptomatic,others,failure,-106,-154,0.4818791946308725
2083,27,58.0608,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,41,Non-White,Male,asymptomatic,others,censoring,81,406,0.5191176470588236
2084,31,82.3284,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,459,White,Male,asymptomatic,others,censoring,50,-373,0.23170731707317074
2085,40,85.7304,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,45,20,0.6656298600311042
2086,27,94.5756,hemophilia,no homosexual,no IV drugs use,90%,prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,481,White,Male,asymptomatic,others,censoring,-124,-354,0.18844807467911318
2087,50,97.9776,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,214,White,Male,symtomatic,others,failure,1,-303,0.2389455782312925
2088,13,48.5352,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,symtomatic,ZDV only,censoring,-12,310,0.6192560175054704
2089,32,53.7516,hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,56,White,Male,asymptomatic,others,censoring,137,155,0.945679012345679
2090,36,76.6584,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,905,White,Male,asymptomatic,others,censoring,-17,113,0.27404343329886244
2091,25,81.1944,hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,366,Non-White,Male,asymptomatic,others,failure,-59,-162,0.379110251450677
2092,47,60.64632,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,845,White,Male,asymptomatic,others,censoring,101,36,0.15937149270482603
2093,18,75.7512,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,638,White,Male,asymptomatic,others,censoring,25,-210,0.18950064020486557
2094,23,57.6072,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,119,White,Male,asymptomatic,ZDV only,censoring,-26,-35,0.13942857142857143
2095,22,60.23808,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,796,Non-White,Male,asymptomatic,others,censoring,157,-943,0.09426057813154587
2096,29,79.38,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,635,Non-White,Male,asymptomatic,others,censoring,-40,-457,0.2318454363757495
2097,41,56.2464,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1775,White,Male,asymptomatic,others,failure,-93,-601,0.2738927738927739
2098,25,73.4832,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,683,White,Male,asymptomatic,others,censoring,-32,-348,0.27941176470588236
2099,30,51.7104,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,858,White,Male,symtomatic,others,censoring,74,-19,0.43545279383429675
2100,20,55.3392,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,629,White,Male,asymptomatic,others,censoring,20,132,0.6509274873524452
2101,32,61.9164,no hemophilia,homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,-33,83,1.3952483801295896
2102,14,48.3084,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,censoring,-53,111,0.42604074402125774
2103,29,57.2,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,108,White,Female,asymptomatic,others,censoring,93,139,0.42124542124542125
2104,48,77.2,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,774,White,Male,asymptomatic,ZDV only,censoring,24,23,1.0256410256410255
2105,37,82.7,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,745,White,Male,asymptomatic,others,censoring,123,-223,0.31130434782608696
2106,27,64.5,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,453,White,Male,asymptomatic,others,censoring,149,-335,0.2083058668424522
2107,23,74.5,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,100,Non-White,Male,asymptomatic,others,censoring,-57,-70,0.425
2108,18,80.4,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,963,White,Male,symtomatic,others,censoring,216,436,0.35038084874863984
2109,47,84.0,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,205,White,Male,asymptomatic,others,censoring,360,973,0.34594594594594597
2110,38,82.7,hemophilia,no homosexual,no IV drugs use,80%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,731,White,Male,asymptomatic,others,failure,105,145,0.31784841075794623
2111,25,78.5,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,490,White,Male,asymptomatic,others,censoring,125,321,0.2910662824207493
2112,16,57.8,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,888,White,Male,asymptomatic,others,censoring,134,146,0.9272300469483568
2113,22,85.9,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,530,White,Male,asymptomatic,ZDV only,censoring,51,71,0.5204301075268817
2114,27,85.8,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,45,412,0.18333333333333332
2115,18,77.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,488,White,Male,asymptomatic,others,failure,173,8,0.3230769230769231
2116,23,66.2,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1327,White,Male,asymptomatic,others,censoring,76,-42,0.4610051993067591
2117,22,99.6,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,50,151,0.7563291139240507
2118,33,73.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,868,Non-White,Male,symtomatic,ZDV only,censoring,154,599,0.2664796633941094
2119,41,55.0,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,866,White,Male,asymptomatic,others,censoring,92,-1045,0.17105263157894737
2120,36,60.0,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,failure,-321,-192,0.929559748427673
2121,24,71.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,334,White,Male,asymptomatic,ZDV only,censoring,111,32,0.4727272727272727
2122,23,70.9,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1181,White,Male,asymptomatic,others,censoring,-223,-212,0.4263261296660118
2123,21,52.3,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,24,White,Male,asymptomatic,ZDV only,failure,-234,-283,0.43730242360379346
2124,25,70.5,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,26,White,Male,asymptomatic,others,censoring,160,1024,0.10975853123129116
2125,26,55.0,no hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,378,White,Female,symtomatic,others,failure,12,-83,0.19272125723738626
2126,16,55.0,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,791,Non-White,Male,asymptomatic,others,failure,1,-143,0.20754716981132076
2127,24,66.0,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,769,White,Male,asymptomatic,others,failure,110,91,0.8863636363636364
2128,25,65.0,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,754,White,Male,asymptomatic,others,censoring,-11,-251,0.375
2129,16,63.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,753,White,Male,asymptomatic,ZDV only,failure,-85,-75,0.5476190476190477
2130,25,78.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,905,White,Male,asymptomatic,others,censoring,126,-82,0.7358490566037735
2131,20,72.4,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Female,asymptomatic,others,censoring,158,-224,0.2795138888888889
2132,27,80.2872,hemophilia,no homosexual,no IV drugs use,70%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,2078,White,Male,asymptomatic,others,censoring,-99,99,0.35274725274725277
2133,39,64.8648,hemophilia,no homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,1042,White,Male,asymptomatic,others,failure,23,-137,0.75
2134,21,53.298,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,842,White,Male,asymptomatic,others,censoring,-43,159,0.2709447415329768
2135,17,102.9672,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,417,Non-White,Male,asymptomatic,ZDV only,censoring,-155,-729,0.21205230244457077
2136,53,69.8544,hemophilia,homosexual,no IV drugs use,90%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,753,Non-White,Male,asymptomatic,others,censoring,-55,-350,0.30122214234363764
2137,14,60.0,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,ZDV only,failure,3,839,0.16616616616616617
2138,45,77.3,hemophilia,no homosexual,no IV drugs use,100%,no prior antiretroviral therapy (no ZDV),ZDV-Therapy befor randomisation,0,White,Male,asymptomatic,others,censoring,19,-359,1.0293785310734462
